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INTRODUCTION 1-15 
 Pharmaceutical analysis includes both quantitative and qualitative analysis. 
Qualitative analysis reveals the chemical identification of the species in the 
sample or yields information about the identification of atomic or molecular 
species or function groups in the sample. Quantitative analysis establishes the 
relative amount of one or more of these species, or analytes, in numerical terms. 
 Pharmaceutical products formulated with more than one drug, typically 
referred to as combination products, are intended to meet previously unmet 
patients need by combining the therapeutic effects of two or more drugs in one 
product. These combination products can present daunting challenges to the 
analytical chemist responsible for the development and validation of analytical 
methods. The official test methods that results from these processes are used by 
quality control laboratories to ensure the identity, purity, potency, and 
performance of drug products. 
 
Basic criteria for new method development of drug analysis: 
 The drug or drug combination may not be official in any pharmacopoeias 
 A proper analytical procedure for the drug may not be available in the 
 literature due to patent regulations. 
 Analytical methods for the quantitation of the drug in biological fluids 
 may not be available. 
 Analytical methods for a drug in combination with other drugs may not be 
 available. 
 The existing analytical procedures may require expensive reagents and 
solvents. It may also involve cumbersome extraction and separation 
procedures and these may not be reliable.  
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Reasons for developing newer analytical methods for drugs: 
 Marketed drug may not be official in pharmacopoeias. 
 Literature search may not contain complete analytical procedure for such 
 drugs. 
 No proper method may be available for drug in the form of formulation 
 due to interference caused by pharmaceutical excipients. 
 Procedures for the estimation of drug in biological fluids may not be 
 available. 
 Analytical techniques may not be available for the drugs in combination 
 with other drugs. 
 Expenses may be more for reagents and solvents used in existing 
 procedures. 
CHROMATOGRAPHY 
 Chromatography was invented and named by the Russian botanist  
Mikhail Tsweet at the beginning of the twentieth century. He employed the 
techniques to separate various plant pigments such as chlorophylls and 
xanthophyll by passing solution of these compounds through a glass column 
packed with finely divided calcium carbonate. 
 Chromatography is unique in the history of analytical methodology and is 
probably the most powerful and versatile technique available to modern analyst. 
In a single procedure it can separate a mixture into its individual components and 
simultaneously determine quantitatively the amount of each component present.  
 The samples may be gaseous, liquid or solid in nature and may range in 
complexity from a single substance to a multicomponent mixture containing 
widely differing chemical species. Furthermore, the analysis can be carried out, 
one extreme, on a very costly and complex experiment, and at other, on a simple, 
inexpensive thin layer plate. 
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 In all chromatography separations the samples is transported in a mobile 
phase, which may be gas, a liquid, or a supercritical fluid. This mobile phase is 
then forced through an immiscible stationary phase, which is fixed in place in a 
column or on a solid surface. The two phase are chosen so that the components of 
the sample distribute themselves between the mobile and stationary phase to 
varying degrees. Those components that are strongly retained by the stationary 
phase move only slowly with the flow of mobile phase. In contrast, components 
that are weakly held by the stationary phase travel rapidly. As a consequences of 
these differences in mobility, sample components separate into discrete bands, or 
zones, that can be be analysed qualitatively and or quantitatively.    
 The chromatographic method of separation, in general, involves the 
following steps: 
 Adsorption  
 Separation of the adsorbed substances by the mobile phase. 
 Recovery of the separated substances by a continuous flow of the mobile 
 phase;     the method being called elution. 
 Qualitative and quantitative analysis of the eluted substances 
 
HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY (HPTLC) 
 HPTLC is a well-known and versatile separation method which shows a 
lot of advantages in comparison to other separation techniques GC and HPLC as it 
requires personnel with minimum technical training and not very sophisticated 
laboratory facilities. 
 Availability of disposable TLC/HPTLC plates, the problem caused by 
samples with high matrix contents, which block the HPLC columns and likely to 
give ghost peaks, is eliminated. HPTLC system is automated and controlled 
throughout by software and is fully reproducible and standardised cGMP-
compliant technique. 
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 Field of application virtually covers all classes of substances such as drugs, 
pesticides, glycosides, fatty acids, carbohydrates, aflatoxins, metals, foodstuff, 
environments and clinical samples. 
 
Advantage: 
 No cumbersome sample preparation needed as pre-coated plates are 
 disposable. 
 Total sample rather than just portion of the sample that elutes from the 
 column (HPLC/GC) occupies the chromatogram(sample integrity). 
 Sample components are stored on the plate, allowing repeated analysis. 
 Multiple samples can be run simultaneously under identical conditions. 
 Similarities and differences are immediately apparent as both sample and 
standard are applied on the same plate and chromatographic conditions 
leading to better analytical precision and accuracy. 
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Various steps involved in HPTLC chromatography 
 
 
 
 
           Selection and optimization           Pre-washing  
                     of mobile phase                 of pre-coated plates 
 
                                                                       
                     Saturation of chamber   Pre-conditioning of layer   
 
 
 
                                                                                         
       
            UV- Visible/fluorescent                                                                                                                            
                                          
                                                                  derivatization 
 
 
 
 
 
 
 
Selection of sorbent layers 
Sample and standard preparation 
Application of standard and the sample 
Chromatographic development   
Quantitative evaluation 
Detection of analytes 
Documentation 
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Pre-coated plates 
 Pre coated plates with different support materials are glass, aluminum, 
plastic and with different sorbent layers are available in different formats and 
thickness. Plates with sorbent thickness of 100-250µm are used for qualitative and 
quantitative analysis. 
 Pre coated plate contain 1-2% organic polymeric binder. These binders 
provide smooth abrasive resistant surface and effectively ensure binding of even 
smallest articles of silica gel to different back materials. 
 
Plate pre-washing:  
 The TLC plate is fully over run by methanol and dry. 
Activation of pre-coated plates 
o Freshly open box of plates do not require activation. 
o Done by placing in an oven at 110-120ºc for prior to spotting. Aluminum 
sheets should be kept in between two glass plates and placing in oven at 
110-120ºc for 15 minutes.  
Application of sample 
 Usual TLC syringe volume is 100µL. The Linomat V automatic applicator 
- nitrogen gas sprays. Band wise application-better separation–high response to 
densitometer. 
Selection of mobile phase 
Normal phase  
o The Stationary phase used is polar and mobile phase is non polar.  
o Non polar compounds eluted first because of lower affinity with stationary 
 phase.  
o Polar compounds retained because of higher affinity with the stationary 
 phase. 
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Reversed phase 
 Stationary phase is non polar, Mobile phase is polar, Polar compounds 
eluted first because of lower affinity with stationary phase, Non-Polar compounds 
retained because of higher affinity with the stationary phase. 
 
Pre-conditioning: 
a. Chamber saturation has pronounced influence on the separation profile. 
When the plate is introduced into an unsaturated chamber, the solvent 
evaporates from the plant mainly at the solvent front. 
b. By lining with filter paper prior to development, solvent vapours soon get 
 uniformly distributed throughout the chamber. 
c. Twin Trough glass chamber used for plate development. 
 
Detection 
o Camag TLC scanner 3 
o Detection under UV light is first choice  
o Spots of fluorescent compound can be seen at 254nm(short wavelength) or 
 366nm(long wavelength) 
o Densitometric measurement of other planar objective equipped with 
 different lamps (D2 & W). 
 
  
 Introduction 
 
 
 
Department of Pharmaceutical Analysis  8 
 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 
 Liquid chromatography (LC) is the generic name used to describe any 
chromatographic procedure in which the mobile phase is liquid. 
 
 In the early years Liquid chromatography was a slow separation technique 
performed in vertical columns by gravity flow. Later developments have greatly 
improved its speed and versatility. The increase in speed has been achieved by 
pumping the solution through the column at inlet pressure up to and sometime 
excessing 1000psi. The gains in versatility have come about through the use of 
smaller diameter, high surface area particles and other unique developments in 
packing structures and surface. This led to an increase in resolution and 
introduced the concept of HPLC.   
 
PRINCIPLE 
 High Performance Liquid chromatography is separation technique where 
solutes migrate through a column containing a micro-particulate stationary phase 
at rates dependant on their distribution ratios. 
 
 These are functions of the relative affinities of the solute for the mobile 
and stationary phases, the elution order depending on the chemical nature of the 
solutes and the overall polarity of the two phases. When a mixture of components 
dissolved in mobile phases is introduced into the column, the compound with 
dissolved in mobile phase is introduced into the column, the compound with lesser 
affinity towards the stationary phase moves faster and hence eluted out of the 
column first. The one with greater affinity towards the stationary phase moves 
slower down the column and hence eluted later. Thus the components are 
separated. 
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HPLC as compared with the classical LC technique is characterised by 
 High resolution. Small diameter (4.6 mm), stainless steel, glass or titanium 
 columns.  
 Column packing with very small (3, 5 and 10μm) particles. 
 Relatively high inlet pressures and controlled flow of the mobile phase.  
 Continuous flow detectors capable of handling small flow rates and 
 detecting very small amounts.  
 Rapid analysis. 
ISOCRATIC GRADIENT 
1. Isocratic, constant eluent 
composition means equilibrium 
conditions in the column and the actual 
velocity of compounds moving through 
the column are constant; analyte-eluent 
and analyte-stationary-phase 
interactions are also constant 
throughout the whole run. 
2. This makes isocratic separations 
more predictable, although the 
separation power (the number of 
compounds which could be resolved) is 
not very high.  
 
3. The peak capacity is low; and the 
longer the component is retained on the 
column, the wider is the resultant peak. 
1. Gradient separation significantly 
increases the separation power of a 
system mainly because of the dramatic 
increase of the apparent efficiency 
(decrease of the peak width).  
 
 
 
2. The condition where the tail of a 
chromatographic zone is always under 
the influence of a stronger eluent 
composition leads to the decrease of the 
peak width. 
 
3. Peak width varies depending on the 
rate of the eluent composition variation 
(gradient slope). 
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BUFFER SELECTION 
 Choice of buffer is typically governed by the desired pH. The typical pH 
range for reversed phase on silica-based packing is pH 2 to 8. It is important that 
the buffer has a pka close to the desired pH since buffer controls pH best at their 
pka.  
 
General considerations during buffer selection: 
 Phosphate is more soluble in methanol/water than in acetonitrile/water or 
 THF/water.  
 Some salt buffers are hygroscopic. This may lead to changes in the 
chromatography (increased tailing of basic compounds, and possibly 
selectivity differences).  
 Ammonium salts are generally more soluble in organic/water mobile 
 phases·  
 TFA can degrade with time, is volatile, absorbs at low UV wavelengths.  
 Microbial growth can quickly occur in buffered mobile phases that contain 
little or no organic modifier. This growth will accumulate on column inlets 
and can damage chromatographic performance. 
  At pH greater than 7, phosphate buffer accelerates the dissolution of silica 
and severely shortens the lifetime of silica-based HPLC columns. If 
possible, organic buffers should be used at pH greater than 7. 
 
BUFFER CONCENTRATION: 
 Generally, a buffer concentration of 10-50 mM is adequate for small 
molecules. Generally, no more than 50% organic should be used with a buffer. 
This will depend on the specific buffer as well as its concentration. Phosphoric 
acid and its sodium or potassium salts are the most common buffer systems for 
reversed phase HPLC. Phosphate buffers can be replaced with sulfonate buffers 
when analyzing organophosphate compounds. 
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Types  
Normal phase chromatography 
 Retention by interaction of the polar surface of stationary phase with polar 
parts of the sample molecules. 
 
Reverse phase chromatography 
 Retention by interaction of the nonpolar hydrocarbon chain of stationary 
phase with nonpolar parts of the sample molecules. 
 
Ion exchange chromatography  
 Differing affinities of ions in solution for oppositely charged ionic 
grouping located on the packing. While the nature of the functional group 
providing the sites for exchange, quaternary ammonium for anions, and sulphonic 
acid for cations, a variety of substrate ranging from cross linked polystyrene, cross 
linked polydextrans, cellulose and silica have been utilised. 
 
Ion pair partition 
 Which contains a counter ion with the opposite charge to that of the ion to 
be analysed, and which will form an ion pair with the ionic sample components. 
The counter ion should contain bulky organic substituents so that the ion pair 
subsequently formed will be hydrophobic in character. 
 
DETECTION: 
 The detection of the separated components in the elute from the column is 
based upon the bulk property of the elute (eg. Its refractive index) or the solute 
property of the individual components (eg. Their ultra violet absorption, 
fluorescence or electrochemical activity). Generally, a detector is selected that will 
respond to a particular property of the substances being separated, and ideally it 
should be sensitive to at least 10-8 g ml-1 and give a linear response over a wide 
concentration range. 
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SYSTEM SUITABILITY PARAMETERS: 
o Resolution  
o Retention time  
o Tailing factor 
o Theoretical plates 
Resolution: 
 Resolution is the parameter describing the separation power of the 
complete chromatographic system relative to the particular components of the 
mixture. 
 
 The resolution Rs of two neighbouring peaks is defined as the ratio of the 
distance between two peak maxima. It is the difference between the retention 
times of two solutes divided by their average peak width. For baseline separation, 
the ideal value of Rs is 1.5. it is calculated by using the formula. 
Retention time: 
 The amount of time between the injection of a sample and its elution from 
the column is known as the retention time; it is given the symbol t R. 
 
Tailing factor (peak asymmetry factor): 
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 The peak half width, b of a peak at 10% of the peak height, divided by the 
corresponding front half width, a gives the asymmetry factor. 
                                 
Theoretical plates (column efficiency): 
 Efficiency N, of acolumn is measured by the number of theoretical plates 
per meter. It is a measure of band spreading of a peak. Similar the band spread, 
higher is the number of theoretical plates, including good column and system 
performance. Column with N ranging from 5000 to 10000 plates/meter are ideal 
for a good system.  
                                    
  
Types of Extraction method 
o Liquid -liquid extraction 
o Solid phase extraction  
o Protein precipitation method 
Liquid -liquid extraction 
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 Liquid–liquid extraction (LLE), also known as solvent extraction and 
partitioning, is a method to separate compounds based on their relative solubility’s 
in two different immiscible liquids, usually water and an organic solvent. It is an 
extraction of a substance from one liquid into another liquid phase. It consists of 
transferring one (or more) solute(s) contained in a feed solution to another 
immiscible liquid (solvent). 
Solid phase extraction: 
 Solid phase extraction (SPE) is a technique designed for rapid, selective 
sample preparation and purification prior to chromatographic analysis. Using 
liquid chromatography principles to control selectivity, SPE provides the sample 
cleanup, recovery and concentration necessary for accurate quantitative analysis. 
 Solid-phase extraction (SPE) is a sample preparation process by which 
compounds that are dissolved or suspended in a liquid mixture are separated from 
other compounds in the mixture according to their physical and chemical 
properties. Analytical laboratories use solid phase extraction to concentrate and 
purify samples for analysis. Solid phase extraction can be used to isolate analytes 
of interest from a wide variety of matrices, including urine, blood, water, 
beverages, soil, and animal tissue. 
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 Solid phase extraction cartridges and disks are available with a variety of 
stationary phases, each of which can separate analytes according to different 
chemical properties. Most stationary phases are based on silica that has been 
bonded to a specific functional group. Some of these functional groups include 
hydrocarbon chains of variable length (for reversed phase SPE), quaternary 
ammonium or amino groups (for anion exchange), and sulfonic acid or carboxyl 
groups (for cation exchange). 
 
Protein precipitation method: 
 This method is least one in bioanalytical. This is a very simple technique 
for extraction of the analyte from the matrix. If protein binding is suspected, then 
protein precipitation prior to sample extraction may be considered.  
 The main requirement for this technique is that the analyte should be freely 
soluble into reconstituting solvent. Preparation of sample through protein 
precipitation achieves separation by conversion of soluble proteins to an insoluble 
state by salting out or by addition of water miscible precipitation solvent or 
organic solvents such as acetone, ethanol, acetonitrile or methanol. 
 Commonly the sample is centrifuged at high speed for sufficient time, all 
the precipitated components of plasma will be settled at the bottom and clear 
supernatant liquid will be separated out. The obtained supernatant liquid can be 
injected directly into the HPLC or it can be evaporated and reconstituted with the 
mobile phase and further cleanup of the sample can be carried out by using micro 
centrifuge at very high speed. 
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QUANTITATIVE ANALYSIS  
Normalisation: 
 The Area% calculation procedure reports the area of each peak in the 
chromatogram as a percentage of the total area of all peaks. Area% does not 
require prior calibration and does not depend upon the amount of sample injected 
within the limits of the detector. No response factors are used.  
 If all components respond equally in the detector and are eluted, then 
Area% provides a suitable approximation of the relative amounts of components. 
 
External Standard Method: 
 External standard method involves the use of a single standard or up to 
three solutions. The peak area or the height of the sample and the standard use are 
compared directly. One can also use the slope of the calibration curve based on 
standard that contain known concentration of the compound of interest. 
 
Internal standard Method: 
 A widely used technique of quantitation involves the addition of an 
internal standard to compensate for various analytical errors. A known compound 
of a fixed concentration is added to the known amount of samples to give separate 
peaks in the chromatogram to compensate for the losses of the compounds of 
interest during sample pretreatment steps. The accuracy of this approach 
obviously dependence on the structural equivalence of the compound of interest 
and the internal standard. RF = standard area or peak heightݏݐ𝑎݊݀𝑎ݎ݀ ܿ݋݊ܿ݁݊ݐݎ𝑎ݐ𝑖݋݊  
 
 
 
STANDARD ADDITION METHOD: 
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 A known amount of the standard compound is added to the ample solution 
to be estimated. This method is suitable if sufficient amount of the sample is 
available and is more realize in the sense that it allow calibration in the presence 
of excipients or other components. 
 
 An important aspect of the method of standard addition is that the response 
prior to spiking additional analyte, it should provide a reasonable S/N ratio(> 10), 
otherwise the result will have poor precision.         
 
APPLICATIONS OF HPLC 
 The HPLC has several applications in the fields of pharmacy, forensic, 
environment and clinical. It also helps in the separation and purification of 
compound.  
 Pharmaceutical Applications: The pharmaceutical applications include 
controlling of drug stability, dissolution studies and quality control. 
  Environmental Applications: Monitoring of pollutants and detecting 
components of drinking water. 
 Forensic Applications: Analysis of textile dyes, quantification of drugs 
and steroids in biological samples. 
 Food and Flavour Applications: Sugar analysis in fruit juices, detecting 
polycyclic compounds in vegetables, analysis of preservatives. 
 Clinical Applications: Detecting endogeneous neuropeptides, analysis of 
biological samples like blood and urine. 
 
 
ANALYTICAL METHOD DEVELOPMENT 
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 Analytical methods are intended to establish the identity, purity, physical 
characteristics and potency of the drugs that we use. Methods are developed to 
support drug testing against specifications during manufacturing and quality 
release operations, as well as during long-term stability studies. Methods may also 
support safety and characterization studies or evaluations of drug performance. 
According to the International Conference on Harmonization (ICH), the most 
common types of analytic procedures are:  
a. identification tests, 
b. quantitative tests of the active moiety in samples of API or drug product or 
 other selected component(s) in the drug product, 
c. quantitative tests for impurities’ content, 
d. Limits tests for the control of impurities. 
 
 Method development is a continuous process that progresses in parallel 
with the evolution of the drug product. The notion of phase-appropriate method 
development is a critical one if time, cost, and efficiency are concerns. The goal 
and purpose of the method should reflect the phase of drug development. During 
early drug development, the methods may focus on API behavior. They should be 
suitable to support pre-clinical safety evaluations, pre-formulation studies, and 
prototype product stability studies. As drug development progresses, the analytical 
methods are refined and expanded, based on increased API and drug product 
knowledge. The methods should be robust and uncomplicated, while still meeting 
the appropriate regulatory guidelines. 
 
 
 
 
 
BIOANALYTICAL METHOD  
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 A bio-analytical method is a set of procedures involved in the collection, 
processing, storage, and analysis of a biological matrix for a chemical compound. 
The most widely accepted guideline for method validation is the ICH guideline 
Q2 (R1), which is used both in pharmaceutical and medical science. 
 Bio-analytical method validation (BMV) is the process used to establish 
that a quantitative analytical method is suitable for biomedical applications. 
Characterization of the stability of analytes in biological samples collected during 
clinical studies together with that of critical assay reagents, including analyte 
stock solutions, is recognized as an important component of bio-analytical assay 
validation. 
 Bio-analytical method validation includes all of the procedures that 
demonstrate that a particular method used for quantitative measurement of 
analytes in a given biological matrix, such as blood, plasma, serum, or urine, is 
reliable and reproducible for the intended use. 
 The quality of these studies is directly related to the quality of the 
underlying Bio-analytical data. It is therefore important that guiding principles for 
the validation of these analytical methods be established and disseminated to the 
pharmaceutical community. 
 Bio-analytical method validation is vital not only in terms of regulatory 
submission but also for ensuring generation of high quality data during drug 
discovery and development. BMV assures that the quantification of analyte in 
biological fluids is reproducible, reliable and suitable for the application. 
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ANALYTICAL VALIDATION BIOANALYTICAL VALIDATION 
Specificity /selectivity: 
 Identification test 
 Determination of impurity 
 assay 
Selectivity: 
 Analyses of blank samples of 
the appropriate biological 
matrix should be obtained from 
at least six sources 
 Ensured at LLOQ 
Accuracy: 
 Assay - drug substance and drug 
 product 
 Impurities – samples spiked 
 with known amounts of 
 impurities 
 Recommended data  
1. minimum of 3 concentration 
levels covering the specified 
range 
2. reported as % recovery 
Accuracy: 
 replicate analysis of samples  
 measured using a minimum of 5 
determinations per 
concentration 
 mean value within 15% 
 it should not deviate more than 
 20% 
Precision: 
 repeatability 
 intermediate 
 reproducibility expressed as  
* standard deviation  
* relative standard deviation 
Precision: 
 5 determinations per 
 concentrations 
 It should not exceed 20% of 
 CV. 
Division: 
 Within run precision 
 Between run precision 
 Introduction 
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Limit of detection: 
 Based on visual evaluation 
 Based on signal to noise 
 Based on SD of response and 
 slope  
 
DL = 3.3 σ/ S 
σ = standard deviation of response 
S = slope of calibration  curve 
 
Limit of quantitation: 
 Based on visual evaluation  
 Based on signal to noise 
 Based on SD 
o QL = 10 σ/ S 
 
Limit of detection: 
 The lowest amount of analyte 
 can be detected but not 
 quantified. 
 The lowest amount of a 
reference solution that can be 
detected and others can be 
detected in biological sample. 
 
 
Limit of quantitation: 
LLOQ: 
 At least 5 times the response 
 compared to blank  
 Identifiable, discrete, 
reproducible, back calculated 
concentration. 
ULOQ: 
 Reproducible and back 
 calculated concentration 
 Not exceed 15% CV 
 Accuracy within 15% of 
 nominal concentration. 
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 Linearity: 
Evaluated by 
 Visual inspection 
 Statistical method 
 *minimum 5 concentration I 
recommended. 
 
Linearity: 
 Directly proportional to the 
concentration of the analyte in 
the sample. 
 5 concentrations levels should 
bracket the upper and lower 
concentration levels evaluated 
during study. 
Robustness: 
 It should show the reliability of 
an analysis with respect to 
deliberate variations in method 
parameters. 
 pH 
 m/p ratio 
 temperature,  
 flow rate  
Robustness: 
 To measure for the 
susceptibility of a method to 
small chances that might during 
routine analysis. 
Stability:  
 Long term stability 
 Freeze/ thaw stability 
 In process stability 
 Processed sample stability. 
 
 
 
 
 
 
 
 
 
 
HERPES ZOSTER     
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            Herpes zoster is a skin rash that occurs due to varicella zoster virus (the 
same virus that causes chicken pox). A person acquires chicken pox usually 
during childhood, which is a self-limiting disease most of the time. This virus then 
remains dormant in nerve cells of the body for months to years and may again 
reactivate during adulthood to cause herpes zoster also known as shingles.  
        
 Herpes zoster occurs in patients who have a decrease in body's resistance 
power. With decreasing immunity, the virus reactivates, begins to multiply and 
then moves along the nerve fibres towards the skin. It is commonly seen in elderly 
people as their immune system weakens. Other patients at risk are cancer patients 
on chemotherapy or radiotherapy, patients with organ transplant and HIV infected 
patients.  
                                            
 
 
 2-3 days prior to the skin rash, patients may have burning pain or tingling 
in one area of the skin, which is usually on one side of body. This is followed by 
appearance of blisters on a red base again in same area of skin. These blisters last 
for two to three weeks, during which pus may appear, then they crust and finally 
begin to disappear leaving behind a depigmented area on the skin. The pain may 
last longer and sometimes pain is severe enough to require painkillers.  
 Introduction 
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 Brivudine is an analogue of the nucleoside thymidine. The active 
compound is brivudine 5'-triphosphate, which is formed in 
subsequent phosphorylations by viral (but not human) thymidine kinase and 
presumably by nucleoside-diphosphate kinase. Brivudine 5'-triphosphate works 
because it is incorporated into the viral DNA, but then blocks the action of DNA 
polymerases, thus inhibiting viral replication. 
 
 Brivudine is used for the treatment of herpes zoster in adult patients. It is 
taken orally once daily, in contrast to aciclovir, valaciclovir and other antivirals. A 
study has found that it is more effective than aciclovir. 
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REVIEW OF LITERATURE  
 The need of survey of literature is to see what has and has not been 
investigated and identify data sources that other researchers have used. To learn 
how others have defined and measured key concepts and develop alternative 
research projects. Review of literature helps to demonstrate understanding and 
ability to critically evaluate research in the field and to provide evidence that may 
be used to support one’s own findings. 
 Pritam Jain et al., (2012) reported stability indicating HPTLC method for 
determination of cefpodoxime proxetil in bulk and tablet dosage form. The 
chromatographic conditions used for separation was silica gel 60 RP-18 f254 and 
mobile comprised of toluene: methanol: chloroform (4: 2: 4 v/v). The Rf value 
was found to be 0.55. The linearity was found to be 100-600ng/band for 
cefpodoxime with correlation coefficient of 0.998. The method was successfully 
applied to pharmaceutical formulation. 
 Laxman  Prajapati et al., (2016) have developed a new simple, precision, 
sensitive and validated HPTLC method for simultaneous estimation of cefepime 
hydrochloride and sulbactum sodium.the chromatographic conditions are  Silica 
Gel G60F254 HPTLC Plates using the mobile phase of chloroform: ethyl alcohol: 
Diethyl amine: water (12:7:1:0.4V/V). The Retention Factor (Rf) was found to be 
0.17 for cefepime hydrochloride and 0.76 for sulbactam sodium respectively. 
Cefepime hydrochloride and sulbactam sodium showed linear response at 
concentration range 4-20 µg/band and 2-10 µg/band. The Correlation co-efficient 
(r2) for cefepime hydrochloride and sulbactam sodium was found to be 0.9997 
and 0.9997 respectively.   
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AIM AND OBJECTIVE 
 
 Cefixime, Cefpodoxime, Cefepime are antibiotic drugs under the class of 
cephalosporin antibiotics. These drugs are used to treat respiratory tract infections, 
skin infections and urinary tract infections. 
 Brivudine is an antiviral drug (herpes zoster virus). The FDA approved 
brivudine  June 29, 2011 to treat shingles ((herpes zoster). 
 Literature reveals very few analytical techniques for the estimation of 
cefpodoxime and cefepime from tablets. Also there is no HPTLC analytical 
method reported for the cefixime.  
 Literatures have proven that there are no analytical method reported for the 
brivudine in formulation as well as biofluids like plasma. 
Hence the major objective of the present research work is, 
 Development and validation of HPTLC method for determination of 
cefixime, cefpodoxime, and cefepime in bulk and pharmaceutical dosage 
form. 
 Development and validation of HPTLC and HPLC method for estimation 
 of brivudine in bulk and pharmaceutical dosage form. 
 Development and validation of bioanalytical method for the estimation of 
 brivudine in human plasma. 
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DRUG PROFILE18-21 
CEFIXIME 
Name                          :   Cefixime 
IUPAC Name             : (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-   
[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
Empirical Formula   :  C16H15N5O7S2 
Structure Formula    :   
                                           
 
Molecular Weight     :  453.452 g/mol  
Description      :  white powder 
Solubility         :  methanol, water    
Melting point             :  218-225 °C 
Bioavailability           :  40% - 50% 
Protein Binding  :   60% 
Storage                   :  Refrigerator 25oC 
Category       :  Antibiotic   
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Action and use       : The bactericidal action of Cefixime is due to the inhibition 
of cell wall synthesis. It binds to one of the penicillin 
binding proteins (PBPs) which inhibits the final 
transpeptidation step of the peptidoglycan synthesis in the 
bacterial cell wall, thus inhibiting biosynthesis and arresting 
cell wall assembly resulting in bacterial cell death.   
Available dosage forms : Tablet, syrup, suspension, powder, Capsule 
Brands  : AIM-200, cefi D S, cemax, Penixime, suprax 
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CEFPODOXIME  PROXETIL 
Name                       :  Cefpodoxime  proxetil 
IUPAC Name                   :  (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-
(methoxyimino)acetamido]-3-(methoxymethyl)-8-
oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-
carboxylic acid 
.Empirical Formula   : C15H17N5O6S2 
Structure Formula          :   
 
Molecular Weight       :    427.58g/mol  
Description      :  white powder 
Solubility                          :  methanol, DMSO   
Melting point                   :  111-113oC 
Bioavailability                 :   50 % 
Protein Binding               :  21-29% 
Storage                             : 25oC   
Category                      :  Antibiotic Agent   
 
 
 
 
Drug Profile` 
 
 
 
Department of Pharmaceutical Analysis  30 
Action and use        : Cefpodoxime is a bactericidal agent that acts by 
inhibition of bacterial cell wall 
synthesis. Cefpodoxime has activity in the presence of 
some beta-lactamases, both penicillinases and 
cephalosporinases, of Gram-negative and Gram-
positive bacteria. 
Available dosage forms        :  Tablet , suspension 
Brands   : ALTIPOD 200, BALPOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CEFEPIME 
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Name         : cefepime 
IUPAC Name         : 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-
(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-
methylpyrrolidin-1-ium 
Empirical Formula   : C19H24N6O5S2 
Structure Formula   :   
 
Molecular Weight    :  450.56 g/mol  
Description      :  white powder 
Solubility      :   methanol, DMSO   
Melting point   :  111-113oC 
Bioavailability :  100 % 
Protein Binding     :  15% 
Storage      :  25oC   
Category     :  Antibiotic Agent   
Action and use        : Cephalosporins exert bactericidal activity by interfering 
with bacterial cell wall synthesis and inhibiting cross-
linking of the peptidoglycan. The cephalosporins are also 
thought to play a role in the activation of bacterical cell 
autolysins which may contribute to bacterial cell lysis. 
  
Available dosage forms       :  Powder for injection  
Brands   :   cefudix, cefwin, Biopime, C-pime  
BRIVUDINE 
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Name               : Brivudine 
IUPAC Name   :  5-[(E)-2-bromoethenyl]-1-[(2R,4S,5R)-4-hydroxy-5-    
(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione 
.Empirical Formula  :  C11H13BrN2O5 
Structure Formula      :   
                                           
Molecular Weight     : 333.135 g/mol  
Description      : White powder 
Solubility      :  Soluble in methanol, DMSO    
Melting point              : 165-166oC  
Bioavailability :   30 % 
Protein Binding      :  >95% 
Storage                         :  25oC   
Category       : Antiviral Agent   
Action and use          Brivudine is an analogue of the nucleoside thymidine. 
The active   compound is brivudine 5'-triphosphate, 
which is formed in subsequent phosphorylations by viral 
(but not human) thymidine kinase and presumably 
by nucleoside-diphosphate kinase. 
Drug Profile` 
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 Brivudine 5'-triphosphate works because it is 
incorporated into the viral DNA, but then blocks the 
action of DNA polymerases, thus inhibiting viral 
replication. 
Available dosage forms : Tablet  
Brands : Zostex 
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MATERIALS AND INSTRUMENTS 
 
CHEMICALS AND SOLVENTS USED 
 Water for HPLC 
 Methanol HPLC grade, AR grade 
 Ortho phosphoric acid AR grade 
 Triethyl amine AR grade 
 Distilled water 
 All the above chemicals and solvents were supplied by S.D. Fine 
Chemicals Ltd., India, Qualigens Fine Chemicals Ltd., Mumbai, India, Sigma-
aldrich Chemicals Pvt. Ltd., Maharashtra, India. 
MATERIALS USED 
 Pre-coated silica gel 60F254 on aluminium sheets were procured from 
Merck, Germany. 
 Phenomenex luna, C18 column (250mm×4.0mm, 5μm). 
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INSTRUMENTS USED 
 
 Shimadzu digital electronics balance 
 pH meter Elico Pvt. Limited, India.  
 Camag HPTLC system (with TLC Scanner-3, Win CATS  software  and 
Linomat 5 as application device) 
 Shimadzu HPLC system with SPD-M10 A VP system PDA with 20μl 
fixed volume manual injector and LC-MS solution software.  
 Jasco V-630 spectrophotometer with a pair of 1 cm quartz Cuvette. 
EQUIPMENTS USED 
 Sonicator (Leelasonic ultrasonic sonicator) 
 Centrifuge (Eppendorf Mini Spin) 
 Borosil micro pipet (AUTOCLAVABLE) 
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR     
DETERMINATION OF CEFIXIME IN BULK AND                        
PHARMACEUTICAL DOSAGE FORM 
Selection of plate: 
Pre-coated silica gel G60F254 on aluminium sheet was selected for the 
study. 
Selection of solvent: 
Methanol was selected as a solvent because cefixime is soluble in 
methanol. 
Selection of wavelength: 
The sensitivity of HPTLC method depends upon the proper selection of 
wavelength for UV detection. An ideal wavelength is the one that give maximum 
absorbance and good response for the drug to be detected at the lower 
concentration. 
Selection of optimum mobile phase 
 The selection of the mobile phase is perhaps the most important parameter 
to achieve efficient thin layer chromatography separation. A solvent system that 
would give dense compact spot and good separation from solvent front and 
application position was to be selected. Initially different solvent systems were 
tried and observations were as given below: 
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Solvent system Observation 
Toluene: ethyl acetate: methanol 
(4.5: 4.5: 1 % v/v/v) Spot moving but not clear spot 
Toluene: ethyl acetate: methanol 
(0.5: 1.5: 8 % v/v/v) Drug moving along with solvent front 
Ethyl acetate: Methanol: water    
(4:6:1 % v/v/v) Higher Rf value 
Ethyl acetate: Methanol: water   
 (4.5: 5: 0.5 %v/v) Compact spot 
 Among these systems, Ethyl acetate: Methanol: water was selected 
because this system gave good symmetric peak. 
Optimization of chamber saturation time 
   The above fixed mobile phase was added to one side of a twin trough 
chamber and different saturation times from 10 to 20 minutes were tried.  It was 
found that a saturation time of more than 15 minutes caused fluctuations in the     
Rf value with edge effect. Hence a saturation time of 15 minutes was fixed for 
further studies. 
Fixed experimental conditions 
Stationary phase   : Pre-coated silica gel G60F254aluminium sheets 
Mobile phase                 :  Ethyl acetate: Methanol: water (4.5: 5: 0.5 %v/v) 
Chamber saturation       :    15 minutes 
Migration distance         :  80 mm 
Band width                       :  6 mm  
Slit dimension                : 5 × 0.45 mm 
Source of radiation           : Deuterium lamp 
Scanning wave length    : 292 nm 
Rf value of cefixime : 0.58 ± 0.02 
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VALIDATION OF THE METHOD 
            The validation of the developed method was carried out in terms of 
linearity, accuracy, limit of detection (LOD), limit of quantification (LOQ), inter 
and intra-day precision and stability studies as per ICH guidelines. 
Limit of detection (LOD) and limit of quantification (LOQ) 
  LOD and LOQ were determined by applying decreeasing amount of the 
drug in triplicate on the plate. The lower concentration at which the peak is 
detected is called limit of detection. The lowest concentration at which the peak is 
qunantified is called limit of quantification.  
 
Linearity and range 
A 100µg/ml solution of cefixime was prepared in methanol. Aliquots of 2, 
2.5, 3, 3.5, 4, and 4.5µl of cefixime were applied on the plate. The plate was 
developed, scanned and peak areas were noted. Linear regression data showed a 
good correlation coefficient over a concentration range of 200-450 ng/band.  
Accuracy  
 In order to ensure the suitability and reliability of proposed method, 
recovery studies were carried out. It was done by mixing known quantities of the 
standard drug with the analysed sample formulation and the contents were 
reanalysed by proposed method. Recovery studies were carried out at 80% and 
120% levels.  
Precision  
Precision of method was demonstrated by: 
i. Intra-day precision 
ii. Inter-day precision 
iii. Repeatability 
Experimental Section 
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a) Repeatability of sample application 
b) Repeatability of sample measurement 
Intra-day precision 
 Intraday precision was studied by different concentration in linearity range 
of the drug for several times on the same day and by calculating % RSD. 
Intra-day precision: 
 Intraday precision was studied by standard drug at two concentrations in 
the linearity range of the drug for three days over a period of one week and % 
RSD was calculated. 
Repeatability: 
Repeatability of sample application was carried by spotting  3.5µl     of 
drug solution is six times on pre coated TLC plate followed by development of 
plate and % RSD was calculated. 
Repeatability of measurement was determined by spotting 3.5µl   of 
drug solution on a pre-coated TLC plate and developed the plate and scanned six 
times and % RSD was calculated. 
Robustness: 
 The robustness of the method is its ability to remain unaffected by small 
change in practical conditions. Here the effect of change in condition such as ratio 
of mobile phase (±0.5%) and saturation time (±5min) were studied to prove 
robustness. 
 
 
Stability of chromatographic plate: 
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 When the developed chromatographic plate is exposed to atmosphere the 
analyte are likely to decompose. Hence it is necessary to study the stability of 
drug on plate. It was studied by scanning the plate at different time intervals and 
peak areas were compared with the peak area of freshly scanned plate. The 
developed plate was found to be stable for about   8 hours for cefixime. 
ANALYSIS OF FORMULATION 
Twenty tablets each containing 200mg of cefixime were taken and the 
average weight was calculated. They were finely pulverized and the quantity of 
homogenised powder equivalent to 10mg of cefixime was transferred to a 100ml 
volumetric flask and up to volume with methanol. Then the solution was filtered 
using whattmann filter paper followed by application of the solution on pre coated 
TLC plate. After development the plate was scanned at 292nm and the peak area 
were noted. The amount of cefixime present in each tablet was calculated and 
tabulated.  
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR     
DETERMINATION OF CEPODOXIME PROXETIL IN BULK AND   
PHARMACEUTICAL DOSAGE FORM 
Selection of plate: 
Pre-coated silica gel G60F254 on aluminium sheet was selected for the 
study. 
Selection of solvent: 
Methanol was selected as a solvent because cefpodoxime is soluble in 
methanol. 
Selection of wavelength: 
The sensitivity of HPTLC method depends upon the proper selection of 
wavelength for UV detection. An ideal wavelength is the one that give maximum 
absorbance and good response for the drug to be detected at the lower 
concentration. 
Selection of optimum mobile phase 
 The selection of the mobile phase is perhaps the most important parameter 
to achieve efficient thin layer chromatography separation. A solvent system that 
would give dense compact spot and good separation from solvent front and 
application position was to be selected. Initially different solvent systems were 
tried and observations were as given below: 
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Solvent system Observation 
Toluene: ethyl acetate : methanol 
(4.5: 4.5 : 1 % v/v/v) Drug moved but not clear spot 
Toluene: ethyl acetate : methanol 
(4:4:2 % v/v/v) Drug moved along with solvent front 
Methanol: Ethyl acetate: toluene                
(1.5:3:5.5 %v/v) Compact spot 
 Among these systems, Ethyl acetate: Methanol: toluene was selected 
because this system gave good symmetric peak. 
Optimization of chamber saturation time 
   The above fixed mobile phase was added to one side of a twin trough 
chamber and different saturation times from 10 to 20 minutes were tried.  It was 
found that a saturation time of more than 15 minutes caused fluctuations in the  
Rf value with edge effect. Hence a saturation time of 15 minutes was fixed for 
further studies. 
Fixed experimental conditions 
Stationary phase   : Pre-coated silica gel G60F254 aluminium sheets 
Mobile phase                 :  Methanol: Ethyl acetate: toluene (1.5:3:5.5 %v/v) 
Chamber saturation          :    15 minutes 
Migration distance         :  80 mm 
Band width                     : 6 mm 
Slit dimension                : 5 × 0.45 mm 
Source of radiation         : Deuterium lamp 
Scanning wave length     :     280 nm 
Rf value of cefpodoxime  :    0.53 ± 0.02 
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VALIDATION OF THE METHOD 
              The validation of the developed method was carried out in terms of 
linearity, accuracy, limit of detection (LOD), limit of quantification (LOQ), inter 
and intra-day precision and stability studies as per ICH guidelines. 
Limit of detection (LOD) and limit of quantification (LOQ) 
  LOD and LOQ were determined by applying decreeasing amount of the 
drug in triplicate on the plate. The lower concentration at which the peak is 
detected is called limit of detection. The lowest concentration at which the peak is 
qunantified is called limit of quantification.  
 
Linearity and range 
A 100µg/ml solution of cefpodoxime was prepared in methanol. Aliquots 
of 1, 1.5, 2, 2.5and 3µl of cefpodoxime were applied on the plate. The plate was 
developed, scanned and peak areas were noted. Linear regression data showed a 
good correlation coefficient over a concentration range of 100-300 ng/band.  
Accuracy  
 In order to ensure the suitability and reliability of proposed method, 
recovery studies were carried out. It was done by mixing known quantities of the 
standard drug with the analysed sample formulation and the contents were 
reanalysed by proposed method. Recovery studies were carried out at 80% and 
120% levels.  
Precision  
Precision of method was demonstrated by: 
 Intra-day precision 
 Inter-day precision 
Repeatability 
 Repeatability of sample application 
 Repeatability of sample measurement 
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Intra-day precision 
 Intraday precision was studied by different concentration in linearity range 
of the drug for several times on the same day and by calculating % RSD. 
Intra-day precision: 
 Intraday precision was studied by standard drug at two concentrations in 
the linearity range of the drug for three days over a period of one week and % 
RSD was calculated. 
Repeatability: 
Repeatability of sample application was carried by spotting  3.5µl     of 
drug solution is six times on pre coated TLC plate followed by development of 
plate and % RSD was calculated. 
Repeatability of measurement was determined by spotting 3.5µl   of 
drug solution on a pre-coated TLC plate and developed the plate and scanned six 
times and % RSD was calculated. 
Stability of chromatographic plate: 
 When the developed chromatographic plate is exposed to atmosphere the 
analyte are likely to decompose. Hence it is necessary to study the stability of 
drug on plate. It was studied by scanning the plate at different time intervals and 
peak areas were compared with the peak area of freshly scanned plate. The 
developed plate was found to be stable for about   8 hours for cefpodoxime. 
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ANALYSIS OF FORMULATION 
Twenty tablets each containing 200mg of cefpodoxime were taken and the 
average weight was calculated. They were finely pulverized and the quantity of 
homogenised powder equivalent to 10mg of cefpodoxime was transferred to a 
100ml volumetric flask and up to volume with methanol. Then the solution was 
filtered using whattmann filter paper followed by application of the solution on 
pre coated TLC plate. After development the plate was scanned at 292nm and the 
peak area were noted. The amount of cefpodoxime present in each tablet was 
calculated and tabulated.  
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR 
DETERMINATION OF CEFEPIME IN BULK AND  
PHARMACEUTICAL DOSAGE FORM 
Selection and pre washing of plate 
 A pre coated silica gel G60F254 on aluminium sheet was selected for the 
study. Pre washing o the plate was done with methanol and then it was activated 
by keeping in an oven at 115oC for 10 mins. 
 
Selection of wavelength 
 The sensitivity of HPTLC method depends upon the proper selection of 
wavelength of UV detection. An ideal wavelength is that the one that give 
maximum absorbance and good response for the drug to be detected at lower 
concentration. The   spectrum of cefepime was shown λmax at 285nm. Hence it was 
selected as the detection wavelength. 
 
Development of optimum mobile phase 
 A solvent system that would give dense compact spots and good 
separation from solvent front and application position was to be selected for the 
study. Initially, different solvents system were tired and observations were as 
given below in table 1. 
 
Solvent system Observation 
methanol : water: chloroform 
(8: 1: 1 % v/v/v) No movement of spots was observed 
Ethyl acetate: ethanol: methanol 
(6:2:3 % v/v/v) No movement of spots was observed 
Toluene: acetone: methanol 
(6;3.5;0.5) No movement of spots was observed 
Methanol: water: ethanol 
(4: 1.5: 2 % v/v/v) Drug moved along with the solvent front 
methanol : water: chloroform 
(7: 2: 1 % v/v/v) Drug moved but not clear spot 
methanol : water: chloroform         
(6: 3: 1 % v/v/v) Compact spot 
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Optimization of chamber saturation 
 The above fixed mobile phase was added to one side of twin trough 
chamber and different saturation times from 5 to 20min were tried. It was found 
that a saturation time of less than 10min caused fluctuation in Rf value and edge 
effect. Hence a saturation of 15min was fixed. 
Fixed experimental conditions 
Stationary phase   :  Pre-coated silica gel G60F254 aluminium sheets 
Mobile phase                 :     Methanol: water: chloroform (6: 3: 1 % v/v/v) 
Chamber saturation         :     15 minutes 
Migration distance          :  80 mm 
Band width                     :      6 mm 
Slit dimension                :     5 × 0.45 mm 
Source of radiation          :     Deuterium lamp 
Scanning wave length    :      285 nm 
Rf value of cefepime     :     0.44 
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VALIDATION OF THE METHOD 
              The validation of the developed method was carried out in terms of 
linearity, accuracy, limit of detection (LOD), limit of quantification (LOQ), inter 
and intra-day precision and stability studies as per ICH guidelines. 
Limit of detection (LOD) and limit of quantification (LOQ) 
  LOD and LOQ were determined by applying decreeasing amount of the 
drug in triplicate on the plate. The lower concentration at which the peak is 
detected is called limit of detection. The lowest concentration at which the peak is 
qunantified is called limit of quantification.  
Linearity and range 
A 100µg/ml solution of cefixime was prepared in methanol. Aliquots of 5, 
10, 15, 20, and 25µl of cefixime were applied on the plate. The plate was 
developed, scanned and peak areas were noted. Linear regression data showed a 
good correlation coefficient over a concentration range of 500-2500ng/band.  
Accuracy  
 In order to ensure the suitability and reliability of proposed method, 
recovery studies were carried out. It was done by mixing known quantities of the 
standard drug with the analysed sample formulation and the contents were 
reanalysed by proposed method. Recovery studies were carried out at 80% and 
120% levels.  
Precision  
Precision of method was demonstrated by: 
 Intra-day precision 
 Inter-day precision 
Repeatability 
 Repeatability of sample application 
 Repeatability of sample measurement 
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Intra-day precision 
 Intraday precision was studied by different concentration in linearity range 
of the drug for several times on the same day and by calculating % RSD. 
Intra-day precision: 
 Intraday precision was studied by standard drug at two concentrations in 
the linearity range of the drug for three days over a period of one week and % 
RSD was calculated. 
Repeatability: 
Repeatability of sample application was carried by spotting  15µl     of 
drug solution is six times on pre coated TLC plate followed by development of 
plate and % RSD was calculated. 
Repeatability of measurement was determined by spotting 15µl   of drug 
solution on a pre-coated TLC plate and developed the plate and scanned six times 
and % RSD was calculated. 
Robustness: 
 The robustness of the method is its ability to remain unaffected by small 
change in practical conditions. Here the effect of change in condition such as ratio 
of mobile phase (±0.5%) and saturation time (±5mins) were studied to prove 
robustness. 
Stability of chromatographic plate: 
 When the developed chromatographic plate is exposed to atmosphere the 
analyte are likely to decompose. Hence it is necessary to study the stability of 
drug on plate. It was studied by scanning the plate at different time intervals and 
peak areas were compared with the peak area of freshly scanned plate. The 
developed plate was found to be stable for about 24 hours for cefepime. 
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ANALYSIS OF FORMULATION 
Ten formulation of Powder for injection (1g/10ml) of cefepime was taken 
and the average weight was calculated. They were finely pulverized and the 
quantity of homogenised powder equivalent to 10mg of cefepime was transferred 
to a 100ml volumetric flask and up to volume with methanol. Then the solution 
was filtered using whattmann filter paper followed by application of the solution 
on pre coated TLC plate. After development the plate was scanned at 285nm and 
the peak area were noted. The amount of cefepime present in each tablet was 
calculated and tabulated.  
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR    
ESTIMATION OF BRIVUDINE IN BULK AND                        
PHARMACEUTICAL DOSAGE FORM 
Selection of plate: 
Pre-coated silica gel G60F254 on aluminium sheet was selected for the 
study. 
Selection of solvent: 
Methanol was selected as a solvent because Brivudine is soluble in 
methanol. 
Selection of wavelength: 
The sensitivity of HPTLC method depends upon the proper selection of 
wavelength for UV detection. An ideal wavelength is the one that give maximum 
absorbance and good response for the drug to be detected at the lower 
concentration. 
Selection of optimum mobile phase 
 The selection of the mobile phase is perhaps the most important parameter 
to achieve efficient thin layer chromatography separation. A solvent system that 
would give dense compact spot and good separation from solvent front and 
application position was to be selected. Initially different solvent systems were 
tried and observations were as given below: 
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Solvent system Observation 
Methanol : Chloroform(3:7 v/v) 
Drug moved along with solvent front 
Methanol : Chloroform(4:6 v/v) 
Drug moved along with solvent front 
Methanol : Chloroform(1:9 v/v) 
Higher Rf value 
Methanol:Chloroform: toluene 
(2:5:3v/v/v) Compact spot 
 Among these systems, Methanol: Chloroform: toluene was selected 
because this system gave good symmetric peak. 
Optimization of chamber saturation time 
   The above fixed mobile phase was added to one side of a twin trough 
chamber and different saturation times from 10 to 20 minutes were tried.  It was 
found that a saturation time of more than 15 minutes caused fluctuations in the     
Rf value with edge effect. Hence a saturation time of 15 minutes was fixed for 
further studies. 
Fixed experimental conditions 
Stationary phase   : Pre-coated silica gel 60 F254 aluminium sheets 
Mobile phase                 :  Methanol: Chloroform: toluene  (2:5:3v/v/v) 
Chamber saturation       :    15 minutes 
Migration distance         :  80 mm 
Band width                     : 6 mm 
Slit dimension                : 5 × 0.45 mm 
Source of radiation        :       Deuterium lamp 
Scanning wave length    : 301 nm 
Rf value of brivudine : 0.50 ± 0.02 
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VALIDATION OF THE METHOD 
              The validation of the developed method was carried out in terms of 
linearity, accuracy, limit of detection (LOD), limit of quantification (LOQ), inter 
and intra-day precision and stability studies as per ICH guidelines. 
Limit of detection (LOD) and limit of quantification (LOQ) 
  LOD and LOQ were determined by applying decreeasing amount of the 
drug in triplicate on the plate. The lower concentration at which the peak is 
detected is called limit of detection. The lowest concentration at which the peak is 
qunantified is called limit of quantification.  
 
Linearity and range 
A 100µg/ml solution of brivudine was prepared in methanol. Aliquots of 
0.5, 1, 1.5, 2, 2.5 and 3µl of brivudine were applied on the plate. The plate was 
developed, scanned and peak areas were noted. Linear regression data showed a 
good correlation coefficient over a concentration range of 50-300 ng/band.  
Accuracy  
 In order to ensure the suitability and reliability of proposed method, 
recovery studies were carried out. It was done by mixing known quantities of the 
standard drug with the analysed sample formulation and the contents were 
reanalysed by proposed method. Recovery studies were carried out at 80% and 
120% levels.  
 
 Precision  
Precision of method was demonstrated by: 
 Intra-day precision 
 Inter-day precision 
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Repeatability 
 Repeatability of sample application 
 Repeatability of sample measurement 
Intra-day precision 
 Intraday precision was studied by different concentration in linearity range 
of the drug for several times on the same day and by calculating % RSD. 
Intra-day precision: 
 Intraday precision was studied by standard drug at two concentrations in 
the linearity range of the drug for three days over a period of one week and % 
RSD was calculated. 
Repeatability: 
Repeatability of sample application was carried by spotting  2µl     of 
drug solution is six times on pre coated TLC plate followed by development of 
plate and % RSD was calculated. 
Repeatability of measurement was determined by spotting 14µl   of drug 
solution on a pre-coated TLC plate and developed the plate and scanned six times 
and % RSD was calculated. 
Robustness: 
 The robustness of the method is its ability to remain unaffected by small 
change in practical conditions. Here the effect of change in condition such as ratio 
of mobile phase (±1% of methanol) and saturation time (±3min) were studied to 
prove robustness. 
 
Stability of chromatographic plate: 
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 When the developed chromatographic plate is exposed to atmosphere the 
analyte are likely to decompose. Hence it is necessary to study the stability of 
drug on plate. It was studied by scanning the plate at different time intervals and 
peak areas were compared with the peak area of freshly scanned plate. The 
developed plate was found to be stable for about  8 hours for brivudine. 
ANALYSIS OF FORMULATION 
Twenty  tablets each containing 125mg of  brivudine were taken and the 
average weight was calculated. They were finely pulverized and the quantity of 
homogenised powder equivalent to 10mg of brivudine was transferred to a 100ml 
volumetric flask and up to volume with methanol. Then the solution was filtered 
using whattmann filter paper followed by application of the solution on pre coated 
TLC plate. After development the plate was scanned at 301nm and the peak area 
were noted. The amount of brivudine present in each tablet was calculated and 
tabulated.  
 
 
 
 
 
 
 
 
 
 
DEVELOPMENT OF VALIDATION RP-HPLC METHOD FOR 
ESTIMATION OF BRIVUDINE IN BULK AND PHARMACEUTICAL 
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Selection of stationary phase: 
 Brivudine is a polar drug, hence in the HPLC method a column C18 was 
used for the separation and estimation of brivudine from tablet dosage form. 
Selection of solvent: 
 The drug was readily soluble in methanol and showed good stability. So 
methanol was selected as solvent. 
Selection of wavelength: 
 Good analytical separation can be obtained only by careful selection of 
wavelength for the detection. This choice requires knowledge of the UV spectrum 
of the sample component. A UV spectrum of brivudine was recorded in methanol 
which showed in maximum absorbance at 254nm and it was selected for the 
study. 
OPTIMIZATION OF CHROMATOGRAPHY CONDITIONS: 
Optimization of mobile phase 
 Optimization of mobile phase was carried out in order to obatain ideal 
peak of brivudine. 
 The mobile phase system consisting of ortho phosphoric acid and 
methanol was optimized for their and pH of the buffer. 
Effect of ratio: 
 The effect of ratio was studied by varying strength such as 45:55, 
50:50,40:60, 60:40,65:35.From which a ratio of  40:60  was selected for further 
study. 
 
Effect of pH: 
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 Keeping the ratio of mobile phase constant (40:60 % v/v) the 
chromatograms were recorded at different pH between 3.4 –7. A good resolution 
and symmetrical peak was obtained at a pH of 6.5 and selected for further studies. 
FIXED CHROMATOGRAPHY CONDITIONS 
Chromatographic method  :  RP-HPLC 
Stationary phase :  phenomenox luna, C18 column 
(250mm*4.0mm,5µ) 
Mobile phase :  1% O-phosphoric acid: methanol 
Ratio of mobile phase   : 40: 60 
Detection wavelength :  254nm 
Flow rate : 0.8ml/min 
Retention time : 5.1 
Validation of the method  
 The development HPLC method was validated according to ICH 
guidelines in term of specificity, linearity, accuracy, precision, robustness and 
LOD and LOQ. 
Specificity: 
 It was studied by injecting the mobile phase, and found that no additional 
peaks were appeared and no interference at the retention time of brivudine. The 
peak purity index was also noted. 
 
Linearity and range: 
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 From the stock solution of brivudine (100mcg/ml), standard solutions were 
prepared in the concentration range 0.5-3mcg/ml in methanol. These solutions 
were injected into HPLC system and chromatograms were recorded. The peak 
areas of these chromatograms were measured at 254nm. A calibration graph was 
plotted with measured concentration against peak areas. The slope, intercept, and 
coefficient values were calculated. 
Accuracy: 
 To confirm accuracy of the method a known quantity of standard drug was 
added with the preanalysed formulation and the contents were reanalyzed by the 
proposed HPLC method. It was carried out at 80 & 120% level. 
Precision: 
 The precision of the method was determined by performing 
 Intra – day precision  
 Inter-day precision 
 Repeatability  
Intraday precision: 
 Intraday precision was determined by injecting standard solution in 
between linearity range  1.5mcg/ml & 2mcg/ml   were injected three times on the 
same day and % RSD was calculated. 
Interday precision: 
 Interday precision was determined by injecting standard solution in 
between linearity range  1.5mcg/ml & 2mcg/ml    were injected for three days and 
% RSD was calculated. 
Repeatability: 
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 Repeatability of injection was determined by injecting standard solutions 
1mcg/ml     for six times, noted peak areas and % RSD was calculated. 
Limit of detection and limit of quantitation: 
 LOD & LOQ were calculated in terms of signal to noise ratio. LOD is the 
lowest concentration of the analyte that can produce a response detectable above 
the noise level of the system, typically, three times the noise level. 
Robustness: 
In order to determine the robustness of the method, slight change were 
made in the practical condition, like flow rate, organic solvent and pH. The 
standard brivudine  was injected and observed in each condition. 
Stability of solution:  
 The standard solution of brivudine was kept under room temperature. It 
was injected periodically, stability was studied by looking for any change in 
retention time, resolution and peak shape, when compared to chromatograms of 
freshly prepared solutions. The solution was stable for   hours under room 
temperature.  
System suitability parameters: 
 The system suitability parameters like peak area, tailing factor, theoretical 
plate count, resolution, and retention time were calculated from the standard 
chromatograms. 
 
 
ANALYSIS OF FORMULATIONS  
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 Twenty tablets of each tablet containing 125mg of brivudine were taken 
for the study and average weight was determined.  The powder of tablets 
equivalent to 10mg of brivudine was weighed and transferred to 100ml standard 
flask and it was dissolved in small portion of methanol, then the volume was made 
up. it was filtered and further dilutions were made and injected into fixed 
chromatographic system and the peak area was measured from which the amount 
present/tablet was calculated. 
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DEVELOPMENT AND VALIDATION OF BIOANALYTICAL METHOD 
FOR THE ESTIMATION OF BRIVUDINE IN HUMAN PLASMA 
Chromatographic conditions:  
The HPLC system for brivudine consist of mobile phase is 1% O-
phsophoric acid: Methanol (40:60), stationary phase is C18 and detection 
wavelength at 254nm. The RT of brivudine was observed at 5.1min. 
Preparation of standard stock solution: 
 The stock solution of 100µg/ml brivudine was prepared by dissolving in 
methanol and stored volumetric flask. Standard working solution of brivudine was 
prepared containing the concentrations of 0.5mcg/ml-3mcg/ml of brivudine. 
OPTIMIZATION OF EXTRACTION PROCEDURE: 
Selection of internal standard: 
 To select internal standard (IS) different drugs (100mcg/ml of each) like 
lamivudine, acyclovir, ledipasvir, sofosbuvir, diclofenac sodium, aspirin were 
tired. Sofosbuvir sodium was selected as it gave symmetrical peak and had good 
resolution from brivudine. 
Optimization of extraction solvent and volume: 
 The protein precipitation technique was preferred to extract brivudine from 
plasma. Based on solubility of two organic solvents, such as methanol, DMSO 
were tried to achieve maximum recovery of brivudine from spiked plasma. Also 
different volumes like 0.1ml, 0.2ml, 0.3ml, 0.5ml were of each organic solvent 
was tried to optimize procedure. 
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Fixed extraction procedure: 
 To a clean and dry centrifuge tube (eppendrof tube), 100 µl of human 
plasma and 100 µl of aliquots of standard drug solution (0.5mcg/ml-3mcg/ml) 
were added and vortexed for 2minutes and 100 µl of internal standard was added 
and vortexed for 3minutes and 1ml of methanol was added to above the solution 
and vortexed for 5minutes. This solution was centrifuged at 1000 rpm for 
15minutes. The clear supernatant solution (20 µl) was filtered through syringe 
membrane filter and injected in optimized chromatographic condition. 
VALIDATION OF THE METHOD  
Specificity: 
 Specificity of the above developed extraction method was demonstrated as 
follows. The blank plasma samples were extracted using the optimized procedure 
and chromatogram was recorded. It was observed for any interference at retention 
time of drug and internal standard peak. 
Linearity range: 
 Linear regression data was studied between concentration and peak area 
ratio of drug to internal standard over a concentration range of 0.5mcg/ml-
3mcg/ml. the standard curve covers the entire range of expected concentration. 
The slope, intercept, and correlation coefficient values were calculated. 
Accuracy: 
 The accuracy of the method was studied at three concentrations in the 
range of 0.5mcg/ml-3mcg/ml. It was observed if the mean value is within 15% of 
the nominal value except at LLOQ, where it should not deviate by more than 20%. 
The deviation of the mean from the nominal value serves as the measure of 
accuracy. 
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Recovery: 
 An important parameter associate with bioanalytical methods is recovery. 
Recovery pertains to the extraction efficiency of an analytical method within the 
limits of variability. The extraction efficiency was explained by recovery studies. 
The standard drug was extracted by the proposed method. The extracts were 
analyzed with the fixed chromatographic conditions. The peak was compared with 
that of unextracted standard peak areas. The peak area response obtained was used 
for determining extraction efficiency. Recovery should be determined by using 
three concentration levels. The % extraction or % recovery was calculated by 
using the followed formula, 𝐴ܾݏ݋݈ݑݐ݁ ݎ݁ܿ݋ݒ݁ݎݕ =  ݎ݁ݏ݌݋݊ݏ݁ ݋݂ ݈ܽ݊ܽݕݐ݁ ݏ݌𝑖݇݁݀ 𝑖݊ݐ݋ ݉ܽݐݎ𝑖ݔሺ݌ݎ݋ܿ݁ݏݏ݁݀ሻݎ݁ݏ݌݋݊ݏ݁ ݋݂ ݈ܽ݊ܽݕݐ݁ ݋݂ ݌ݑݎ݁ ݏݐܽ݊݀ܽ݀ ሺݑ݊݌ݎ݋ܿ݁ݏݏ݁݀ሻ 𝑋 ͳͲͲ 
 
Precision: 
 The precision of the method was carried out at three different 
concentrations in expected concentration range. The precision determined at each 
concentration level if it is not exceeding 15% coefficient of variation (CV) except 
for the LOQ where it should not exceed 20% CV. Precision may be considered at 
three levels: repeatability, inter-day precision, intra-day precision. %𝐶𝑉 =  ݏݐܽ݊݀ܽݎ݀ ݀݁ݒ𝑖ܽݐ𝑖݋݊݉݁ܽ݊  × ͳͲͲ 
Intra-day precision: 
 Intra-day precision was studied the standard drug at three different 
concentrations in the linearity range of drug (high QC, middle QC, and low QC) 
for five times same day and coefficient of variation was calculated. 
Inter-day precision: 
 Inter-day precision was studied the standard drug at three different 
concentrations in the linearity range of drug (high QC, middle QC, and low QC) 
for five times same day and coefficient of variation was calculated. 
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Lower limit of quantitation: 
 The lowest concentration of an analyte in a sample that can be 
quantitatively determined with an acceptable precision and accuracy. 
 
Middle limit of quantification: 
 The middle concentration of analyte in a sample that can be quantitatively 
determined with an acceptable precision and accuracy. 
Higher limit of quantitation: 
 The higher concentration of analyte in a sample that can be quantitatively 
determined with an acceptable precision and accuracy.  
 
Stability: 
 The aim of a stability test is to detect any degradation of the analytes of 
interest during the entire period of sample collection, processing, storing, 
preparing, and analysis. The condition under which the stability is determined is 
largely dependent on the nature of the analyte, the biological matrix, and the 
anticipated time period of storage. Stability should be confirmed for every step of 
sample preparation and analysis, as well as the conditions used for long-term 
storage.  
Short-term stability 
 The stability of the analyte in biological matrix at ambient temperature 
should be evaluated. Three aliquots of low and high concentration should be kept 
for at least 24 hours and then analysed. 
The stability of the drug was studied under the room temperature.  
 
 
Results & Discussion 
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR 
ESTIMATION OF CEFIXIME IN BULK AND  
PHARMACEUTICAL DOSAGE FORM 
 Among various mobile phase system tried the one contain a mixture of 
ethyl acetate: methanol: water (4.5: 5: 0.5 % v/v/v) gave compact dense band was 
chosen for the estimation of cefixime by HPTLC method. The plate used was    
pre-coated silica gel G60F254. The method was for the validated and details are 
given below. 
Linearity and range: 
  A 100µg/ml of cefixime was prepared in methanol. Aliquots of this 
solution (2-4.5µl) were applied on the plate. The plate was developed, scanned 
and peak areas were noted. Linear regression data showed good correlation 
coefficient over a concentration range of (200-450ng/band). The calibration graph 
is shown in fig 1. The slope, intercept, and correlation coefficient values were in 
noted  (table 1). The spectra of band obtained was recorded on HPTLC scanner 
(fig. 2) and the standard densitograms are shown in fig.3 to 8, and calibration data 
was shown table 2.  
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Fig 1 Calibration graph of cefixime (200-450ng/band) 
          
 
 
Table 1: Regression data of cefixime 
Linear regression Cefixime 
 Slope 11.21 
Intercept 593.815 
Correlation coefficient 0.998 
 
Table 2: calibration data for cefixime 
Concentration (ng/band) Peak area 
200 3286.5 
250 3704.8 
300 4095.9 
350 4561.2 
400 4900.4 
450 5368.1 
 
 
Fig.2 spectrum of cefixime band 
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Fig. 3 Densitogram of cefixime 200ng/band 
                   
 
 
 
Fig. 4 Densitogram of cefixime 250ng/band 
Results & Discussion 
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Fig. 5 Densitogram of cefixime 300ng/band 
                    
 
 
Fig .6 Densitogram of cefixime 350ng/band 
Results & Discussion 
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Fig.7 Densitogram of cefixime 400ng/band 
           
 
 
Fig. 8 Densitogram of cefixime 450ng/band 
Results & Discussion 
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Precision 
 The method precision was obtained by repeating the determination of 
standard drug of two selected concentrations (350 & 400ng/band) of cefixime. 
The % RSD was calculated for inter-day, intra-day and repeatability (repeatability 
of sample measurement and sample application respectively) are shown in  
table 3 & 4. 
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Table 3: Intraday and interday precision 
Concentration 
(ng/band) 
Peak area % RSD 
Intraday Interday Intraday Interday 
350 
4466.8 4279.8 
0.9 1.9 4544.2 4328.3 
4483.6 4431.2 
400 
5318.6 5278.9 
0.2 1.4 5341.8 5169.4 
5316.9 5278.7 
                                 
Table 4: Repeatability sample measurement and sample application 
 
Concentration 
(ng/band) 
 
Peak area 
 
%RSD 
Sample 
measurement 
Sample 
application 
Sample 
measurement 
Sample 
application 
400 
5396.8 5298.6 
 
 
0.6 
 
 
 
 
0.9 
 
 
5378.6 5369.8 
5310.0 5241.0 
5318.6 5364.9 
5341.8 5360.1 
5316.9 5300.1 
 
Limit of detection (LOD) and limit of quantitation (LOQ): 
 The lowest concentration of the analyte detectable was found to be 
40ng/band (fig. 9). The lowest concentration of the analyte at which it is 
quantifiable was found to be 100ng/band. 
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Fig.9 LOD of cefixime 40ng/band 
                           
 
 
Robustness  
 The robustness of the method is its ability to remain unaffected by small 
changes in the parameter such as ratio of mobile phase and saturation time. The 
method is said to be robust as minor variation (as shown below) not affected 
quantification. 
 
Parameters Observation 
Ratio of mobile phase ± 0.5 methanol                
(ethyl acetate: methanol: water) 
Slight changes in Rf, but no difference 
in peak area  
Saturation time(15 ± 2minutes) Peak symmetry retained. 
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Stability of chromatographic plate 
 When the developed method chromatographic plate was exposed to 
atmosphere, the analytes are likely to decomposed. Hence it was necessary to 
conduct stability studies of the plate.  
 Stability of the analyte on the plate was studied at different time intervals 
and peak areas were compared with peak area of freshly scanned plate. The 
developed plate was found to be stable for less than 24hrs (table 5). 
 
Table 5: Stability of chromatographic plate 
Time (hr) Concentration(ng/band) Peak area 
0 250 300 
3289.7 
3820.1 
8 250 300 
3189.2 
3879.3 
24 250 300 
3096.1 
3450.0 
 
ANALYSIS OF FORMULATION  
 20 tablets, each containing 200mg of cefixime were taken for the study 
and average weight was determined. Quantity equivalent to10mg of cefixime was 
weighed and transferred to 100ml volumetric flask added 10ml methanol and 
sonicated. It was centrifuged for 30min and made up to volume with methanol. It 
was filtered and used for analysis. 
Recording chromatogram  
 With the fixed chromatographic condition, a suitable volume of sample 
solutions was applied on the precoated TLC plate. The plate was analyzed and 
chromatogram was recorded (fig 10). The UV spectrum of cefixime recorded on 
scanner is shown in fig 11. Peak areas of sample chromatograms were noticed and 
the amount of drugs was calculated, table 6.  
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Fig. 10 Densitogram of Cefixime 250ng/band 
                       
 
Fig. 11: Spectrum of cefixime band 
    
 
 
Table 6: Results analysis of formulation 
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Brand name 
Amount of drug/tablet 
%label claim %RSD* Labeled 
(mg/ tablet) 
Found 
 (mg/ tablet) 
 
ALTIPOD 
200 
 
 
200 
 
195.2 
 
97.6% 
 
0.6 
*average of six observations 
 
Recovery: 
 Recovery studies were carried out at 80% & 120% levels. The percentage 
recovery and percentage % RSD of the results were calculated and shown in table 
7. The value proves the accuracy of the method. 
Table 7: Recovery study 
Levels % Recovery %RSD* 
80          99.81% 0.87 
120           100.9% 0.78 
*Average of six observation 
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR 
DETERMINATION OF CEFPODOXIME IN BULK AND 
PHARMACEUTICAL DOSAGE 
  
 Different mobile phase compositions are tried for development and 
validation of cefpodoxime by HPTLC method. Among these mobile phase system, 
methanol: ethyl acetate: toluene (1.5:3:5.5 %v/v) was selected because in this 
system compact and dense band with good separation were obtained. 
 
Linearity and range: 
 Linear regression data showed a good correlation coefficient over a 
concentration range 100-300ng/band. The calibration data are shown in the table 8 
and the slope, intercept and correlation coefficient values were found are 
presented in table 9 respectively. The calibration graph is shown in fig 12. The 
spectrum recorded on HPTLC scanner (fig 13) and the standard chromatograms 
obtained at different concentrations of cefpodoxime are shown in fig. 14-18. 
Table. 8 calibration data of cefpodoxime 
Concentration(ng/band) Peak area 
100 1230.4 
150 1538.6 
200 1894.2 
250 2184.0 
300 2551.3 
 
Table 9: Regression data of cefpodoxime 
Linear regression Cefpodoxime 
 Slope 8.124 
Intercept 293.581 
Correlation coefficient 0.999 
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Fig. 12 Calibration graph of cefpodoxime 
                      
 
 
Fig. 13spectrum of cefpodoxime band 
                       
 
 
Fig.14 Densitogram of cefpodoxime (100ng/band) 
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Fig.15 Densitogram of cefpodoxime (150ng/band) 
                       
 
 
Fig. 16 Densitogram of cefpodoxime (200ng/band) 
Results & Discussion 
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Fig.17 Densitogram of cefpodoxime (250ng/band) 
 
 
 
Fig.18 Densitogram of cefpodoxime (300ng/band) 
Results & Discussion 
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Precision: 
 The method precision was obtained by repeating the determination of 
standard drug of two selected concentrations (200 & 250ng/band) of cefpodoxime. 
The % RSD was calculated for inter-day, intra-day and repeatability (repeatability 
of sample measurement and sample application respectively) shown in table  
10 & 11. 
 
 
 
 
 
 
 
 
Table.10 Intraday and interday precision 
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Concentration  
(ng/band) 
Peak area %RSD 
Intraday Interday Intraday Interday 
 
200 
1817.7 1800.3  
1.6 
 
1.2 1878.6 1845.9 
1838.6 1820.5 
 
250 
2283.7 2169.8  
1.4 
 
1.6 2178.9 2132.8 
2135.8 2198.7 
 
Table 11: Repeatability sample measurement and sample application 
Concentration 
(ng/band) 
Peak area %RSD 
Sample 
measurement 
Sample 
application 
Sample 
measurement 
Sample 
application 
200 
1817.7 2133.2 
1.4 1.7 
1878.6 2178.0 
1830.1 2135.8 
1856.0 2183.7 
1838.6 2103.8 
1878.6 2135.8 
 
Limit of detection (LOD) and limit of quantitation(LOQ): 
 The lowest concentration of the analyte detectable was found to be 
60ng/band (fig. 19). The lowest concentration of the analyte at which it is 
quantifiable was found to be 100ng/band. 
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Fig.19 LOD of cefpodoxime (60ng/band) 
                               
 
 
Stability of chromatographic plate: 
 Stability of the analyte on the plate was studied at different time intervals 
and peak area were compared with the peak area of freshly developed and scanned 
plate. 
 Stability of the plate was studied at different time intervals and peak areas 
were compared with peak area of freshly scanned plate. The developed plate was 
found to be stable for less than 24hrs (table 12). 
Table. 12 plate stability 
Time (hr) Concentration(ng/band) Peak area 
0 100 250 
1230.4 
1894.6 
8 100 200 
1083.9 
1640.6 
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Preparation of sample solution for cefpodoxime: 
 Each of twenty tablets containing 200mg of cefpodoxime was taken for the 
study and average weight was determined. Quantity equivalent to 10mg 
cefpodoxime was weighed and transferred to 100ml standard flask and after 
dissolving it was made up to volume with methanol. It was filtered and used for 
analysis. 
 
Recording chromatogram: 
 The fixed chromatographic condition, a suitable volume of sample solution 
was applied on the precoated TLC plate. The plate was analyzed and 
chromatogram as recorded. The amount present per tablet, % label claim were 
calculated and shown in table 13. The UV spectrum of spot is shown in fig. 20 and 
chromatogram of formulation is shown in fig 21. 
 
                                  Table. 13 Results of analysis of formulation 
 
Brand 
Amount found  
% Label claim 
 
% RSD Label  
mg/tablet 
Found 
mg/tablet 
BALPOD 200 195.2 97.6% 0.96 
 
 
 
     
 
 
 
 
 
Fig. 20  Spectrum of cefpodoxime band 
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Fig.21 Densitogram of cefpodoxime formulation 
                          
 
 
Recovery: 
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 Recovery studies were carried out at 80% and 100% levels. The 
percentage recovery and percentage RSD of the results were calculated and shown 
in table 14. The value proves the accuracy of the method. 
Table.14 Recovery studies 
Levels % Recovery %RSD* 
80 98.55% 0.51 
100 101.4% 0.82 
*Average of six observation 
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR 
DETERMINATION OF CEFEPIME IN BULK AND PHARMACEUTICAL 
DOSAGE FORM 
 Among various mobile phase system tried the one contain a mixture of 
methanol: water: chloroform (6: 3: 1 % v/v/v) gave compact dense band was 
chosen for the estimation of benfotiamine by HPTLC method. The plate used was 
pre-coated silica gel G60F254. The method was for the validated and details given 
below. 
Linearity and range: 
 A 100µg/ml of cefixime was prepared in methanol. Aliquots of this 
solution (5-25µl) were applied on the plate. The plate was developed, scanned and 
peak areas were noted. Linear regression data showed good correlation coefficient 
over a concentration range of (500-2500ng/band). The calibration graphs are 
shown in fig 22. The slope, intercept, and correlation coefficient values were in 
noted and showen in table 15. The spectra of spot recorded on HPTLC scanner 
(fig 23) and the standard densitograms are shown in fig.24 to 28 and calibration 
data were shown table 16.  
Table: 15 Regression data of cefepime 
Linear regression cefepime 
Slope 1.2 
Intercept 85.36 
Correlation coefficient 0.998 
 
 
 
 
 
Fig.22 calibration graph for cefepime 
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Fig.23 Spectrum of cefepime band 
 
 
 
 
Table: 16 calibration data of cefepime 
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Concentration(ng/band) Peak area 
500 668.1 
1000 1348.8 
1500 1939.6 
2000 2516.5 
2500 3198.5 
 
Fig.24 Densitogram of cefepime 500ng/band 
                         
 
    
 
 
 
 
 
                            Fig.25 Densitogram of cefepime 1000ng/band 
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Fig.26 Densitogram of cefepime 1500ng/band 
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Fig.27 Densitogram of cefepime 2000ng/band 
                          
 
Fig.28 Densitogram of cefepime 2500ng/band 
                        
 
 
Precision: 
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 The method precision was obtained by repeating the determination of 
standard drug of two selected concentrations (1500 & 2000ng/band) of cefepime. 
The % RSD was calculated for inter-day, intra-day and repeatability (repeatability 
of sample measurement and sample application respectively) shown in table  
17 & 18.   
Table: 17 Intraday and interday precision 
Concentration(ng/band) 
Peak area %RSD 
Intraday Interday Intraday Interday 
1500 
1866.0 1808.5 
 
0.8 
 
0.6 
1888.7 1832.8 
1898.0 1823.3 
2000 
2599.0 2513.9 
 
 
0.3 
 
0.4 
2577.7 2514.9 
2589.0 2533.2 
 
Table: 18 Repeatability sample measurement and sample application 
Concentration 
(ng/band) 
Peak area %RSD 
Sample 
measurement 
Sample 
application 
Sample 
measurement 
Sample 
application 
 
 
 
 
2000 
1779.0 1755.9 
 
 
 
1.1 
 
 
 
1.2 
1755.8 1733.6 
1723.4 1799.5 
1763.8 1751.8 
1745.8 1763.8 
1777.1 1763.8 
 
 
Limit of detection (LOD) and limit of quantitation(LOQ): 
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 The lowest concentration of the analyte detectable was found to be 
120ng/band. The lowest concentration of the analyte at which it is quantifiable 
was found to be 250ng/band 
 
Stability of chromatographic plate: 
 When the developed method chromatographic plate was exposed to 
atmosphere, the analytes are likely to decomposed. Hence it was necessary to 
conduct stability of the plate. 
 Stability of the plate was studied at different time intervals and peak areas 
were compared with peak area of freshly scanned plate. The developed plate was 
found to be stable for less than 24hrs (table 19). 
Table. 19 plate stability 
Time (hr) Concentration(ng/band) Peak area 
 
0 
1000 
1500 
1348.8 
1939.6 
 
8 
1000 
1500 
810.0 
1081.1 
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ANALYSIS OF FORMULATION: 
Preparation of sample solution for cefepime: 
 Ten formulation of Powder for injection (1g/10ml) of cefepime was taken 
for the study and. Quantity equivalent to 10mg cefepime was weighed and 
transferred to 100ml standard flask and after dissolving it was made up to volume 
with methanol. It was filtered and used for analysis. 
 
Recording chromatogram: 
 The fixed chromatographic condition, a suitable volume of sample solution 
was applied on the precoated TLC plate. The plate was analyzed and 
chromatogram as recorded. The amount present per tablet, % label claim were 
calculated and shown in table 20. The UV spectrum of spot is shown in fig 29 and 
chromatogram is presented in fig 30. 
 
Fig. 29 Densitogram of cefepime 
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Fig.30 spectrum of cefepimeband 
                           
 
 
Table.20 Results of analysis of formulation 
Brand 
Amount found 
 
% Label claim 
 
% RSD Label 1000mg/ml 
Found 
1000mg/ml 
NOVAPIME 1000 997.2 99.7% 0.37 
 
Recovery: 
 Recovery studies were carried out at 80% and 100% levels. The 
percentage recovery and percentage RSD of the results were calculated and shown 
in table 14. The value proves the accuracy of the method. 
Table.21 Recovery studies 
Levels % Recovery %RSD* 
80 97.9% 0.27 
100 99.8% 0.54 
*Average of six observation 
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR 
ESTIMATION OF BRIVUDINE IN BULK AND PHARMACEUTICAL 
DOSAGE FORM 
 Different mobile phase compositions are tried for development and 
validation of brivudine by HPTLC method. Among these mobile phase system, 
methanol: chloroform: toluene (2:5:3 % v/v) was selected because in this system 
compact and dense band with good separation were obtained. 
 
Linearity and range: 
 Linear regression data showed a good correlation coefficient over a 
concentration range 50-300ng/band. The calibration data are shown in the      
(table 22) and the slope, intercept and correlation coefficient values were found 
are presented in (table 23) respectively. The calibration graph is shown in fig 31. 
The spectrum recorded on HPTLC scanner (fig 32) and the standard 
chromatograms obtained at different concentrations of brivudine are shown in fig. 
33-38. 
 
Table 22: Calibration data for brivudine 
Concentration (ng/band) Peak Area 
50 1389.0 
100 2642.8 
150 3705.8 
200 473101 
250 5578.9 
300 6459.5 
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  Table 23: Regression data for brivudine 
Slope 20.106 
Intercept 565.907 
Correlation coefficient 0.997 
 
Fig. 31 calibration graph of brivudine: 
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Fig. 32 spectrum of brivudine band 
                                 
 
 
Fig. 33 Densitogram of brivudine (50ng/band) 
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Fig. 34 Densitogram of brivudine (100ng/band) 
 
 
Fig. 35 Densitogram of brivudine (150ng/band) 
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Fig. 36 Densitogram of brivudine (200ng/band) 
 
 
Fig. 37 Densitogram of brivudine (250ng/band) 
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Fig. 38 Densitogram of brivudine (300ng/band) 
 
Precision: 
 The method precision was obtained by repeating the determination of 
standard drug of two selected concentrations (150 & 200ng/band) of brivudine. 
The % RSD was calculated for inter-day, intra-day and repeatability (repeatability 
of sample measurement and sample application respectively) shown in table 24 
&25. 
Table.24 Intraday and interday precision 
Concentration 
(ng/band) 
Peak area %RSD 
Intraday Inter day Intraday Inter day 
150 
3770.4 3662.6 
0.9 0.6 3735.6 3657.9 
3772.1 3690.5 
200 
4798.8 4663.1 
0.2 1.4 4744.5 4602.3 
4733.4 4763.1 
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Table. 25 Repeatability sample measurement and sample application 
Concentration 
(ng/band) 
Peak area %RSD 
Sample 
measurement 
Sample 
application 
Sample 
measurement 
Sample 
application 
 
 
 
 
200 
4733.6 4732.6 
 
 
0.6 
 
 
0.5 
4789.5 4769.8 
4786.4 4702.8 
4723.8 4710.3 
4754.9 4728.8 
4712.3 4700.3 
 
 
Limit of detection (LOD) and limit of quantitation(LOQ): 
 The lowest concentration of the analyte detectable was found to be 
30ng/band (fig. 39). The lowest concentration of the analyte at which it is 
quantifiable was found to be 50ng/band. 
Fig . 39 LOD of brivudine (30ng/band) 
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Robustness: 
 The robustness of the method was proven by deliberate changes in 
condition like mobile phase ratio (±0.5ml) and staturation time  (± 3min). the Rf 
values and peak area were found to be similar hence method is said to be robust. 
Stability of chromatographic plate: 
 When the developed method chromatographic plate was exposed to 
atmosphere, the analytes are likely to decomposed. Hence it was necessary to 
conduct stability of the plate. 
 Stability of the plate was studied at different time intervals and peak areas 
were compared with peak area of freshly scanned plate. The developed plate was 
found to be stable for less than 24hrs,(table 26). 
Table 26: plate stability 
Time (hr) Concentration(ng/band) Peak area 
0 250 300 
5578.9 
6459.5 
8 250 300 
5499.0 
6400.1 
24 250 300 
4268.5 
4676.5 
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ANALYSIS OF FORMULATION: 
Preparation of sample solution for Brivudine: 
 Each of twenty tablets containing 125mg of brivudine was taken for the 
study and average weight was determined. Quantity equivalent to 10mg brivudine 
was weighed and transferred to 10ml standard flask and after dissolving it was 
made up to volume with methanol. It was filtered and used for analysis. 
Recording chromatogram: 
 The fixed chromatographic condition, a suitable volume of sample solution 
was applied on the precoated TLC plate. The plate was analyzed and 
chromatogram as recorded. The amount present per tablet, % label claim were 
calculated and shown in table 27. The UV spectrum of brivudine is shown in fig 
40 and chromatogram of spot is shown in fig 41. 
 
 
Fig.40 spectrum of brivudine band 
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Fig.41 Densitogram of brivudine (100ng/band) 
                                
 
 
Table 27: results of analysis of formulation: 
Brand name Amount of drug/tablet %label claim %RSD* Labeled(mg) found(mg) 
Zostex 125 122 97% 0.9 
*Average of six observation 
Recovery: 
 Recovery studies were carried out at 80% and 100% levels. The 
percentage recovery and percentage RSD of the results were calculated and shown 
in table 28. The value proves the accuracy of the method. 
  
Table 28: recovery studies: 
Level % Recovery % RSD* 
80% 101.07% 0.32 
100% 100.9% 0.29 
*Average of six observation  
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DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE 
ESTIMATION OF BRIVUDINE IN BULK AND PHARMACEUTICAL 
DOSAGE FORM 
 Brivudine is a polar in nature hence RP-HPLC method and C18 column 
was used for the HPLC method development for the estimation of brivudine. 
Selection of wavelength: 
 Good analytical separation can be obtained only by careful selection of 
wavelength for the detection (fig.42). The smooth obtained from which 254nm 
was select for a drug. 
Fig. 42: spectrum of brivudine 
                    
 
Selection of mobile phase: 
 For developing HPLC method, mobile phase system containing 1% ortho 
phosphoric acid (pH adjusted with triethyl amine): methanol was tried different 
ratios and different pH. The observation and chromatograms are given below table 
29. A ratio containing 40:60 % v/v and at a pH 6.5 was selected as ideal one. 
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Mobile 
phase 
Ratio 
(% 
v/v) 
chromatograms pH observation 
 
Buffer: 
methanol 
 
50:50 
 
 
3.5 Broad peak 
Buffer: 
methanol 
 
60:40 
 
 
3.5 Split peak 
 
Buffer: 
methanol 
40:60 
 
 
 
6.5 
 
Good peak 
separation 
 
Linearity and range: 
 A calibration graph was plotted with measured peak area against 
concentration. From the graph it was found that brivudine shows good linearity in 
the concentration between 0.5-3.0mcg/ml. The peak area of these solutions was 
measured at 254nm. The slope, intercept, and correlation coefficient values were 
calculated respectively (table 30). The linearity table is shown in table 30. The 
calibration graph and standard chromatogram were obtained and shown in           
fig 43-49. 
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Table 30 Calibration data 
Concentration (µg/ml) Peak Area 
0.5 48264 
1 78565 
105 107762 
2 133056 
2.5 156059 
3 185107 
 
                                  
Fig. 43 Calibration graph of brivudine 
 
 
 
 
 
 
Peak  
area 
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Fig. 44 chromatogram of brivudine (0.5µg/ml) 
 
Fig. 45 chromatogram of brivudine (1 µg/ml) 
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Fig. 46 chromatogram of brivudine (1.5µg/ml) 
 
Fig. 47 chromatogram of brivudine (2µg/ml) 
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Fig. 48 chromatogram of brivudine (2.5µg/ml) 
 
 
Fig. 49 chromatogram of brivudine(3 µg/ml) 
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Precision: 
 Intraday precision was determined by injecting standard solutions in 
between linearity range (1.5 & 2mcg/ml) were injected three times on the same 
day and % RSD was calculated (table 31).  
Interday precision: 
 Interday precision was determined by injecting standard solution in 
between linearity range (1.5&2mcg/ml) were injected for three days and % RSD 
was calculated table 31. 
 
Repeatability: 
 Repeatability of injections was determined by injecting standard solutions 
1mcg/ml for six times, noted peak area and % RSD was calculated table 32. 
 
Table 31: Intraday and interday precision 
Concentration(mcg/ml) 
Peak area %RSD 
Intraday Interday Intraday Interday 
1.5 
107980 109350 
 
0.7 
 
0.9 106476 107314 
107553 108978 
 
2 
130824 130824 
 
0.9 
 
1.0 132389 128418 
129636 128567 
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Table 32: Repeatability sample measurement and sample application 
Concentration 
(mcg/ml) 
Peak area %RSD 
Sample 
measurement 
Sample 
application 
Sample 
measurement 
Sample 
application 
1 
78568 78565 
0.7 0.8 
77792 77982 
77129 77129 
78234 78234 
78564 79001 
78444 77895 
 
Limit of detection and limit of quantitation: 
 The LOD and LOQ were found to be 0.3mcg/ml and 0.5mcg/ml 
respectively.  
Specificity: 
 There were no additional peaks observed while injecting solvents or 
mobile phase alone. The peak purity index of standard brivudine was 0.9997. This 
proves specificity of the method. 
Robustness: 
 In order to demonstrate the robustness of the method, the following 
optimized conditions were slightly changed. 
 ±0.2ml flow rate 
 ±0.5% organic solvent 
 ±0.1pH 
 
 
Stability of solution: 
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 The solution under room temperature was stable for 24 hour and up to 
72hr stable under refrigeration. 
System suitability studies: 
 The system suitability parameters like peak area, tailing factor, theoretical 
plate count, resolution, and retention time were calculated from the standard 
chromatograms table 33. 
 
                            Table 33: system suitability parameters 
Drug Theoretical plate 
(N) 
Retention time (min) Tailing factor 
Brivudine 1963.8 5.1 0.9 
 
Analysis of formulation 
 Twenty tablets each containing 125mg of brivudine was taken for the 
study and average weight was determined. Quantity to 10mg brivudine was 
weight and transferred to 100ml standard flask and it was dissolved and made up 
to volume with methanol. Further dilutions were made and injected. The 
chromatogram is shown in fig 49. The result of analysis of formulation is shown 
in table 34. The peak purity index was found to be 0.9991. 
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Fig. 50  chromatogram of brivudine (1 µg/ml) 
 
Table 34: analysis of formulation: 
Brand 
Amount of drug/tablet 
% label claim % RSD* Label(mg) found(mg) 
Zostex 125 119 95.2% 1.2 
*Average of six observation 
Recovery study: 
 Recovery studies were carried out at 80% and 120% levels. The 
percentage recovery and % RSD of the results were calculated table 35. The high 
% recovery values shows accuracy of the method. 
Table 35: Recovery studies 
Level % Recovery % RSD* 
80 98.9% 0.82 
120 99.12% 0.68 
*Average of six observation 
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DEVELOPMENT AND VALIDATION OF BIOANALYTICAL METHOD 
FOR THE ESTIMATION OF BRIVUDINE IN HUMAN PLASMA 
  
 A HPLC method was developed and employed for employed for 
bioanalytical estimation of brivudine from human plasma. 
 The chromatographic conditions are the mobile phase consist of 1% O-
phosphoric acid : methanol(40:60 % v/v), stationary phase is C18 and detection 
wavelength at 254nm. The RT of brivudine was observed at 5.1min. 
 
Selection of internal standard: 
 In the fixed chromatographic conditions acyclovir and sofosbuvir  were  
injected for the selection of internal standard. Sofosbuvir was selected as internal 
standard, it was well resolved from drug peak with good peak characters. The 
chromatograms are shown in fig 51 & 52. 
Fig.51 chromatogram of acyclovir 
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Fig.52 chromatogram of sofosbuvir 
 
Optimization of extraction procedure: 
 To extract brivudine from plasma, protein precipitation method was tried 
using methanol and DMSO. Different volume of each organic solvent like 0.5ml, 
1.0ml was tried for better recovery. The extraction efficiency was good with 
methanol when compared to all trials. The high recovery was obtained using 
methanol as an extraction solvent and no interfering peaks were observed at the 
retention time of brivudine and internal standard. 
Specificity: 
 Specificity was demonstrated by blank plasma samples and plasma spiked 
with internal standard. They were extracted using the above procedure and 
chromatogram recorded. It was found that there was no interference from blank 
plasma at the retention time of brivudine (5.1min) and internal standard (11.2)  
were shown in Fig.53.  
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Fig.53 Chromatogram of Blank plasma 
 
 
Linearity and range: 
 Linear regression data revealed an excellent linear relationship between 
concentration and peak area ratio. The retention time of brivudine was 5.1 min 
and internal standard 11.2min. The quantity of internal standard spiked was 100µl. 
A calibration curve has shown the linearity in the concentrations range of 
0.5mcg/ml-3mcg/ml with correlation coefficient of 0.9245. The slope, and 
intercept, values -0.00639913 and 0.271063 respectively. The calibration graph is 
shown in fig 54 and calibration data in table 36. The standard chromatogram of 
plasma spiked with brivudine is shown in fig 55-60.  
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Fig. 54 Calibration graph 
                                
 
 
Fig.55 chromatogram for brivudine 0.5mcg/ml 
               
 
 
Fig. 56 Chromatogram for brivudine 0.75mcg/ml 
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Fig.57 chromatogram for brivudine 1.5mcg/ml 
 
 
 
 
Fig.58 chromatogram for brivudine 2mcg/ml 
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Fig.59  chromatogram for brivudine 2.5mcg/ml 
                 
 
 
Fig.60 chromatogram for brivudine 3mcg/ml 
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Table.36 Calibration table of brivudine (Bioanalytical method) 
Concentration 
(mcg/ml) 
Concentration 
of internal 
standard 
Peak area Peak area ratio 
(brivudine/ 
Sofosbuvir(IS)) brivudine sofosbuvir 
0.5 
10mcg/ml 
22427 129038 0.17 
0.75 28034 106577 0.26 
1.5 44290 131524 0.36 
2 61794 122505 0.50 
2.5 85934 124255 0.69 
3 126013 132325 0.95 
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 Accuracy was determined by calculating the ratios of the predicted 
concentration to spiked values and with the precision express as %RSD. The mean 
value should be within 15% of the nominal value except at LLOQ, MLOQ, 
HLOQ where it should not deviate by more than 20%. The deviation of the mean 
from the nominal value serves as the measure of accuracy (table 37). The values 
are obtained with in the deviation limit which proves the accuracy of the method. 
Table 37 Accuracy study 
True concentration 
(mcg/ml) 
Peak area* % deviation from true 
value Limit of 
% 
deviation 
LLOQ MLOQ HLOQ LLOQ MLOQ HLOQ LLOQ MLOQ HLOQ 
0.5 1.5 3 
22427 44290 126013 
4.2 2.3 1.2 15 24589 53432 128511 
26598 41458 128937 
*Average of three observations  
Recovery: 
 Recovery reflects the degree of extraction. In general recovery is impacted 
by the interaction of the analyte with endogenous and/or exogenous components 
of matrix. The peak was compared with that of unextracted standard peak areas. 
The peak area response obtained was used for determining extraction efficiency 
(table 38). The % recovery was more than 50% on every occasion at three 
different levels. 
Table 38 Recovery study 
Concentration (ng/ml) Mean % recovery* 
500 (LLOQ) 51% 
750 (MLOQ) 69% 
3000 (HLOQ) 66% 
*Mean of six observations 
 
Precision: 
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Intraday precision and inter-day precision: 
 Intraday and inter-day precision were estimated by analyzing five replicate 
samples at each concentration on the same day and on five consecutive days. 
Analysis of standard drug at three different concentrations in the linearity range 
(low, middle, high) and coefficient of variation was calculated (table 39 & 40). 
Table. 39 Intraday precision  
Concentration (mcg/ml) Coefficient of variation (CV)* Limit 
0.5 9.4  
Within 15% 1.5 5.2 
3.0 4.9 
*Mean of three concentrations  
Table. 40 Inter-day precision 
Concentration (mcg/ml) Coefficient of variation (CV)* Limit  
0.5 8.5  
Within 15% 1.5 6.9 
3.0 11.6 
*Mean of three concentrations 
 
Lower limit of quantitation: 
 The lowest concentration of an analyte in a sample that can be 
quantitatively determined with an acceptable precision and accuracy fig 61. 
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Fig.60 Lower limit of concentration 0.5mcg/ml 
 
 
Stability: 
 The stability of the drug was studied under the room temperature. The 
stability of brivudine is 6hrs in room temperature (after extraction). 
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SUMMARY AND CONCLUSION 
 In the present study 3 cephalosporin class of drugs (cefixime, 
cefpodoxime, cefepime) and an antiviral drug brivudine were selected and 
HPTLC methods were developed and validated. 
 One RP-HPLC method was also developed and validated for brivudine, 
and the developed HPLC method was applied to estimate the drug in plasma. 
 
ANALYTICAL METHOD DEVELOPMENT: 
HPTLC METHOD: 
 For the determination of cefixime by HPTLC method, a system 
comprising of ethyl acetate: methanol: water (4.5: 5: 0.5 % v/v/v) was selected 
because this system gave good separation with symmetric peak (Rf = 0.58) at the 
selected wavelength of 292nm. Calibration graph was plotted in the concentration 
range of 200-450ng/band(r = 0.998). The developed plate was stable upto 8 hours. 
Limit of detection was found to be 40ng/band and limit of quantification was 
found to be 100ng/spot. This method was successfully applied for the 
determination of cefixime from tablet dosage form. 
 
 For the estimation of cefpodoxime by HPTLC, different mobile phase 
systems were tried with different ratios.  It was found that a system comprising of 
a mobile phase system containing Methanol: ethyl acetate: toluene (1.5: 3: 3.5 
v/v/v) was selected because in this system the drug solutions gave better peak with 
good resolution and also offered an optimum migration (Rf = 0.53) at the selected 
wavelength of 280nm. Linearity was found over the concentration range of       
100-300ng/band (r = 0.999). The slope, intercept and correlation coefficient 
values were found to be 8.1124, 293.581 and 0.999 respectively. 
 
 For the determination of cefepime by HPTLC method, a system 
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comprising of chloroform: methanol: water (1: 6: 3 % v/v/v) was selected because 
this system gave good separation with symmetric peak (Rf = 0.44) at the selected 
wavelength of 285nm. Calibration graph was plotted in the concentration range of 
500-2500ng/spot(r = 0.998).  The developed plate was stable up to 8 hours. Limit 
of detection was found to be 120ng/spot and limit of quantification was found to 
be 500ng/spot. This method was successfully applied for the determination of 
cefepime from tablet dosage form. 
 In the developed HPTLC method brivudine stock solution of 100mcg/ml 
was prepared in methanol. The standard solution and formulation were spotted on 
pre coated silica gel G 60F254 on aluminum sheets which was followed by 
development using methanol: chloroform: toluene (2:5:3 v/v/v) and scanning at 
301nm. The drug gave good symmetrical peak at Rf value of 0.50. It showed a 
linearity range in concentration 50-300ng/band. The slope, intercept and 
correlation coefficient values were found to be 19.87, 623.025 and 0.997 
respectively. 
Parameters HPTLC 
cefixime cefpodoxime cefepime 
Linearity 200-450ng/spot 100-300ng/spot 500-2500ng/spot 
LOD 40ng/spot 60ng/spot 120 ng/spot 
LOQ 100ng/spot 100ng/spot 250ng/spot 
Detection wavelength 292nm 280nm 285nm 
% Label claim 97.6 97.5 99.7 
Theotrical plate 38mm 42mm 39mm 
Asymmetric factor 1 1.1 1 
 
 
 
 
 
 
RP-HPLC METHOD FOR BRIVUDINE: 
Summary & Conclusion 
 
  
 
 
 
Department of Pharmaceutical Analysis  127 
 In the developed RP-HPLC method, optimization of the several 
chromatographic parameters like selection of mobile phase, detection wavelength, 
ratio of mobile phase and flow rate etc were done. A mobile phase system 
consisting of 1% ortho phosphoric acid   (pH 6.5): Methanol (40:60 v/v) was 
selected for the separation of brivudine. With this system a peak with good 
resolution and less peak tailing was obtained at a flow rate of 0.8ml/min. The 
method was validated as per ICH guidelines. 
 
 Calibration curve was plotted using concentration (x) versus peak area(y). 
Linearity of brivudine was found over the range of 0.5 – 3mcg/ml. The correlation 
coefficient value was found to be 0.9995. 
 
Bioanalytical method development: 
 A RP-HPLC method was developed for bioanalytical estimation of 
brivudine from human plasma. A mobile phase system consisting of 1% ortho 
phosphoric acid   (pH 6.5): Methanol (40:60 v/v) was selected for the separation 
of brivudine & sofosbuvir (RT – 5.1 & 11.2) and detection was done at 254nm. 
The method was validated over the range of 0.5-3mcg/ml. The LLOQ is found to 
be 0.5mcg/ml. Intraday and interday precision studies were also carried out and 
variation was less than 15% & within the prescribed limit.  
 
 
 
 
 
 
 
CONCLUSION 
 Cephalosporin class of drugs were selected and analytical methods 
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(HPTLC) were developed for its estimation. The HPTLC methods developed were 
validated as per ICH guidelines and found to be specific, accurate, and precise. 
 The method developed for the cephalosporin (cefixime, cefpodoxime, 
cefepime) can be used in industry for routine analysis to check the amount of the 
drug present in pharmaceutical dosage form. 
 Brivudine is an  antiviral drug which was selected and  analytical methods 
(HPTLC & HPLC) were developed for the  determination of brivudine in bulk, 
pharmaceutical dosage form and in plasma.  
 The bioanalytical method developed is simple and showed good accuracy, 
specificity and reproducible. It can be used for the estimation of Brivudine in 
biofluids. The chromatogram developed was well resolved peak of Brivudine 
without any interference. The developed method could be applied in 
bioequivalence and pharmacokinetic studies. 
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